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Abstract 
 
Midbrain dopaminergic neurons are highly heterogeneous. They differ in their target 
and afferent projections and firing patterns, and therefore in their functional 
properties. The molecular underpinnings of this heterogeneity are largely unknown 
and there is a paucity of markers that distinguish these functional subsets. This thesis 
reports the identification and characterisation of a novel subset of midbrain 
dopaminergic neurons located in the ventral tegmental area that expresses the basic 
helix-loop-helix transcription factor, Neurogenic Differentiation Factor-6 
(NEUROD6). Retrograde fluorogold tracing experiments demonstrate that Neurod6+ 
midbrain dopaminergic neurons project to two distinct septal regions, the dorsal 
lateral and intermediate region of the lateral septum. Loss-of-function studies in mice 
demonstrate that Neurod6 and the closely related family member Neurod1 are both 
specifically required for the survival of this lateral-septum projecting neuronal subset 
during development. These findings underscore the complex organisation of 
midbrain dopaminergic neurons and provide an entry point for future studies of the 
functions of the Neurod6+ subset of midbrain dopaminergic neurons.  
 
Significance Statement  
Midbrain dopaminergic neurons regulate diverse brain functions, including voluntary 
movement and cognitive and emotive behaviours. These neurons are 
heterogeneous and distinct subsets are thought to regulate different behaviours. 
However, we currently lack the means to identify and modify gene function in specific 
subsets of midbrain dopaminergic neurons. The work presented here identifies the 
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transcription factor NEUROD6 as a specific marker for a novel subset of midbrain 
dopaminergic neurons in the ventral midbrain that project to the lateral septum and 
reveals essential roles for Neurod1 and Neurod6 in the survival of these neurons 
during development. My findings highlight the molecular and anatomical 
heterogeneity of midbrain dopaminergic neurons and contribute to a better 
understanding of this functionally complex group of neurons.  
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 — Santiago Ramón y Cajal 
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Chapter 1. Introduction 
1.1 Short History of Dopamine 
Dopamine (DA) was initially synthesised in the early 1900s (Barger and Ewins, 1910; 
Mannich and Jacobsohn, 1910) however this particular catecholamine did not 
become of much interest to scientists until later in the 1950s. DA was for the first time 
detected in mammalian tissues by Goodall in 1951 where it was found in the heart 
and adrenal medulla of sheep (Goodall, 1951). Up until that point, DA was still 
referred to as 3-hydroxytyramine, which was the short form for its proper chemical 
name b-3,4-Dihydroxyphenethylamine and in 1952, Sir Henry Dale coined the name 
“dopamine” (Blaschko, 1952). During this time the idea of DA having its own unique 
biological actions, that may be different from those of other better studied 
catecholamines at the time such as adrenaline and noradrenaline and aside from 
DA’s established role in their synthesis, was not given much attention. The 
identification of dopamine as a neurotransmitter in the brain and not merely just a 
precursor of noradrenaline was demonstrated by the Swedish pharmacologist, Arvid 
Carlsson, in 1957. His work at the time included developing an assay to measure 
dopamine in the brain where he made the observation that the basal ganglia was 
where the highest regional concentration of DA existed (Hornykiewicz, 2008). This 
led on to his experiments on reserpine, an antipsychotic that due to its effects on 
depletion of DA, also produced loss of DA motor control similar to the motor 
impairment observed in clinical features of Parkinsonism. Carlsson went on to show 
that the DA precursor, L-dopa, was effective in the treatment of motor symptoms of 
Parkinsonism and is still considered today as one of the main drug treatments for 
Parkinson’s Disease (PD) patients. Aside from PD, he is also famous for his 
Chapter 1. Introduction 
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‘dopamine theory of schizophrenia’ documenting the role of DA in the development 
of extra-pyramidal side effects of antipsychotic medications. Carlsson and co-
recipients Eric Kandel and Paul Greengard, won the Nobel Prize in Physiology or 
Medicine in the year 2000 for their revolutionary work on dopamine.  
 
1.2 Dopamine Synthesis 
Catecholamines are monoamines which are organic compounds that have a 
benzene with 2 hydroxyl groups at carbons 1 and 2 and a side chain amine. Three 
catecholamines exist in nature; adrenaline, noradrenaline (NA) and DA, which are 
all derived from the amino acid tyrosine. DA synthesis in nervous system tissues is 
a two-step process. Firstly, tyrosine is converted into DOPA in a dehydration process 
catalysed by the enzyme tyrosine hydroxylase (TH). This is the rate-limiting step in 
DA synthesis and uses tetrahydrobiopterin and molecular oxygen. Secondly, the 
decarboxylation of L-DOPA by aromatic-L-amino-acid decarboxylase (AADC) into 
DA. In the brain, DA has several functions in facilitating movement, motivation, 
reward and addictive behaviours.  
 
1.3 Dopamine Signaling  
In the brain, endogenous neurotransmitter DA can act as a ligand by binding to DA 
receptors and modulating downstream DA signalling. DA receptors are metabotropic 
G-protein coupled receptors (GPCRs) and are broadly divided into two main 
subtypes; the D1-like class and D2-like class of DA receptors (Beaulieu and 
Gainetdinov, 2011).  
Chapter 1. Introduction 
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The D1-like family of DA receptor subtypes includes D1 and D5, which are excitatory 
in action since their activation is coupled to Gas which activates adenylyl cyclase. 
This leads to an increase in the concentration of the second messenger cyclic 
adenosine monophosphate (cAMP) resulting in protein kinase A (PKA) activity. This 
DA receptor subtype is uniquely expressed on DA-target postsynaptic cells (Beaulieu 
and Gainetdinov, 2011).  
 
In contrast, the D2-like family of DA receptor subtypes includes D2, D3 (Sokoloff et al., 
2006) and D4 (Rondou et al., 2010), which are inhibitory in action since their 
activation is coupled to Gai which inhibits adenylyl cyclase. This results in a decrease 
in the concentration of cAMP leading to reduced PKA activity (Beaulieu and 
Gainetdinov, 2011). Also, unlike the D1-class, the D2 and D3 receptors are expressed 
both on postsynaptic DA-target cells and presynaptically on DA-producing neurons 
(Sokoloff et al., 2006; Rankin et al., 2010; Rondou et al., 2010). The levels, broad 
expression patterns and various functions of D1 – D5 receptors in the brain are 
summarised in Appendix 7.1. 
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Figure 1-1. Distribution of DA groups in the developing embryonic brain and in 
the adult brain of rodents (cited from Bjorklund and Dunnet, 2007) 
A total of 9 DA groups which include the A8- A16 DA populations within the (a) 
developing embryonic brain and (b) adult brain of rodents. In the adult, these DA 
groups project their axons to a wide range of targets within the brain. 75% of 
neurons that use DA as their primary neurotransmitter are located within the 
midbrain A8, A9 and A10 subpopulation nuclei corresponding to the retrorubral field 
(RRF), substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) 
respectively. These midbrain dopamine (mDA) neurons project their axons to 
regions within the forebrain including multiple cortical and striatal regions.  
 
1.4 The origins of midbrain dopamine neurons 
In the developing embryonic and adult brain, a total of 9 DA groups exist (Figure 1-1). 
These are classified as the A8 – A16 DA groups (Figure 1-1). In the adult brain, 75% of 
total neurons that primarily use dopamine as their neurotransmitter, are located within 
the ventral midbrain within three primary midbrain dopamine (mDA) nuclei (Ang, 2006; 
Wallen and Perlmann, 2003). These mDA subpopulations include the A8 retrorubral field 
(RRF), the A9 substantia nigra pars compacta (SNc) and the A10 ventral tegmental area 
(VTA) mDA subpopulations (Figure 1-2; Stott and Ang, 2013). These midbrain 
dopaminergic (mDA) neurons express the rate-limiting enzyme TH involved in DA 
synthesis (Figure 1-2; Stott and Ang, 2013). These mDA neurons represent a large 
heterogenous mixed population that differ in their anatomical location, cellular 
Chapter 1. Introduction 
 22 
morphology, physiological properties, axonal projections, forebrain targets and 
consequently in their underlying functions. Degeneration of SNc neurons gives rise to 
PD whereas dysfunction of VTA neurons is implicated in several neuropsychiatric 
disorders. This chapter will highlight both the development of these mDA neurons and 
their anatomical, cellular, molecular, physiological and functional heterogeneity.  
 
 
Figure 1-2 The mDA subpopulations: (A8) RRF, (A9) SNc and (A10) VTA 
Immunohistological fluorescence staining for visualisation of mDA neurons using 
an antibody for the rate- limiting enzyme TH on a (A) Coronal section of the adult 
mouse brain at the level of the retrorubral field (RRF) and on a (B) Coronal section 
of the adult mouse brain at the level of the substantia nigra (SNc) and ventral 
tegmental area (VTA) mDA subpopulations. 
  
 
1.5 mDA neuron development 
Neural subtype specification begins with the subdivision of the rostral CNS into broad 
territories; the forebrain, midbrain and hindbrain. These broad regions of the brain 
are patterned along the anterior – posterior and dorsal – ventral axis by signalling 
factors that are secreted from distinct organising centres. These secreted signals in 
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turn activate the expression of specific transcription factors that are required for the 
specification of progenitors into specific neuronal fates whilst tightly regulating their 
proliferation to ensure the generation of precise pool of progenitors. Specific sets of 
transcription factors are expressed in a combinatorial manner across the various 
stages of mDA neuronal development. Firstly, an early differentiation stage where 
mDA progenitor cells differentiate into immature mDA neurons. Secondly, the late 
differentiation stage where immature mDA neurons differentiate further into mature 
mDA neurons. And finally the maintenance and survival of these mature mDA 
neurons from the embryo to adult stages.  
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Figure 1-3 Early development of the mDA domain relies on signalling centres, 
secreted proteins and several transcription factors (cited from Stott and Ang, 
2013) 
(a) Schematic represents the developing anterior end of the neural tube divided 
into the prosencepahlon, mesencephalon, rhombencephalon and the spinal cord. 
The midbrain arises from the mesencephalon, (b) The mDA domain is located at 
the ventral curve of the midbrain region in mice at embryonic (E) day E10 and its 
development is influenced by the anatomical location and secretory factors 
released from the three main mDA organising centres which include the floor plate 
(FP), the roof plate (RP) and the Isthmic Organiser (IsO), (c) Secretory proteins are 
released from each of these areas including Sonic hedgehog (Shh) from the FP, 
FGF8 from the IsO and Wnt1 secreted from multiple areas, (d) Secreted proteins 
from the organising centres then regulate the expression of several transcription 
factors within different midbrain areas for regional specification and induction of 
mDA progenitor cell development.   
 
 
 
1.5.1 Early Midbrain Patterning & Regional Specification of mDA progenitors 
Neuralisation of the ectoderm during gastrulation gives rise to the ‘neural plate’ also 
known as the neuropepithelium. The neural plate folds along its length and the fusing 
of its lateral edges form the dorsal midline of a ‘neural tube’ (Copp et al., 2003). 
Closing of the neural tube allows for the regionalisation of the brain by the formation 
of three vesicles at the anterior end of the embryo; the prosencephalon, 
mesencephalon, rhombencephalon and spinal cord (Stott and Ang, 2013; Figure 1-
3a). Prosoncephalon (forebrain) gives rise to the telencephalon (future cerebral 
cortex, basal ganglia, internal capsule, insular cortex, lateral ventricles and corpus 
callosum) and diencephalon (future thalamus, epithalamus, subthalamus and 
hypothalamus). The Rhombencephalon (hindbrain) gives rise to the metencephalon 
(future cerebellum and pons) and the myelencephalon (future high and low medulla). 
The midbrain (superior and inferior colliculi) arises from the mesencephalon, which 
is the structure that lies between the prosoncephalon and the rhombencephalon in 
the developing neural tube.  
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The regional specification of the mDA domain relies on an important organising 
centre called the Isthmic organiser or Isthmus (IsO) located at the boundary between 
mesencephalon-metencephalon border also known as the midbrain-hindbrain 
boundary (Figure 1-3b). The orthodenticle homeobox 2 (Otx2) and gastrulation brain 
homeobox 2 (Gbx2), are two homeodomain transcription factors that are required for 
establishing the correct positioning and maintenance of the IsO by mutual repression. 
The IsO is formed at the posterior extent of the Otx2 expression boundary and the 
anterior limit of Gbx2 expression (Ang, 2006; Figure 1-3). Loss- of function studies 
of Otx2 and Gbx2 reveal a forward and backward shift of the midbrain/ hindbrain 
boundary, respectively (Broccoli et al., 1999; Millet et al., 1999) highlighting the 
fundamental roles of Otx2 and Gbx2 in IsO maintenance and midbrain patterning. 
 
The midbrain contains two other signalling centres; the floor plate (FP) along the 
ventral midbrain midline and the roof plate (RP) which runs along the dorsal midline 
of the midbrain (Figure 1-3b). Fibroblast growth factor 8 (FGF8) proteins are secreted 
from the IsO, sonic hedgehog (Shh) from the floor plate and Wnt1 from many 
signalling centres (Stott and Ang, 2013; Figure 1-3b,c). Together, these secretory 
proteins are required for the induction of mDA neurons before E9.5 by regulating the 
expression of downstream transcription factors within the midbrain including the 
paired box genes Pax2/5/8, engrailed homeobox genes En1/2 and the LIM 
homeobox gene Lmx1b (Guo et al., 2007; Figure 1-3d).  
Members of the forkhead box family of transcription factors, Foxa1 and Foxa2, 
regulate many phases of mDA neurogenesis in a dose-dependent manner (Ferri et 
al., 2007). Specifically, Foxa1/2 control the specification of mDA progenitors by 
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regulating the expression of downstream genes including Ngn2, Nurr1, En1, Aadc 
and Th (Ferri et al., 2007) during both early- and late- differentiation phases of mDA 
neurons. 
 
1.5.2 mDA Differentiation & Maturation 
Birthdating studies in mice have revealed that between E9.5 and E13.5, mDA 
progenitors exit the cell cycle and undergo an early differentiation phase to generate 
post-mitotic immature mDA neurons (Bayer et al., 1995). Transcription factors 
expressed in mDA progenitor cells that facilitate the neuronal differentiation of mDA 
progenitors into differentiating immature mDA neurons include Ngn2 (Andersson et 
al., 2006a), Msx1 (Andersson et al., 2006b). Mash1 is also expressed in mDA 
progenitors but is not required for their differentiation however is compensatory for 
Ngn2 function in mDA differentiation (Kele et al., 2006). 
Immature mDA neurons migrate ventrally along radial glia fibers (Shults et al., 1990; 
Kawano et al., 1995) from the proliferative ventricular zone (VZ) of the ventral 
midbrain to the intermediate zone (IZ). Here, immature mDA neurons begin 
expression of the immature mDA marker nuclear receptor related 1 (Nurr1; 
Zetterstrom et al., 1997). Nurr1 is expressed in both immature and mature mDA 
neurons and is required for expression of late- differentiation markers, levels of which 
are diminished in Nurr1 conditional mutants (Kadkhodaei et al., 2009). 
The expression of BIII-tubulin, a general neuronal marker, is also initiated at this 
differentiation stage to maintained in mature mDA neurons (Kele et al., 2006).   
While migrating along radial glia, immature mDA neurons undergo a late 
differentiation step and transition from the IZ into the mantle zone (MZ) where in 
addition to expressing the immature markers, they also begin expressing mature 
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mDA markers including AADC, PITX3 and TH (Smidt et al., 2004). At this stage while 
mDA neurons are undergoing late differentiation from immature to mature states, the 
onset of AADC (Ang, 2006) facilitates the conversion of L-DOPA to DA, which is then 
synthesised in mDA neurons during maturation. Other mature mDA markers also 
include the vesicular monoamine transporter 2 (VMAT2) and dopamine transporter 
(DAT). VMAT2 is an internal membrane protein that packages DA from the cytosol 
into synaptic vesicles for vesicular release of DA and other co-neurotransmitters 
such as GABA. DAT is a membrane-spanning protein that pumps DA already 
released in the synapse back into the cytosol of mDA cells for storage before release. 
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Figure 1-4 Stages of mDA differentiation and migration along FP during 
embryonic ventral midbrain development (cited from Stott and Ang, 2013) 
(a) Coronal section at the level of the ventral midbrain in E12 mouse embryonic 
brain exposing the FP region which gives rise to mDA progenitors in the (b) 
proliferative ventricular zone (PZ/ VZ) which then migrate along shafts of radial glia 
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during their early differentiation stage into immature mDA neurons into the 
intermediate zone (IZ) and then late differentiation stage into mature mDA neurons 
reaching the mantle zone (MZ). (c) Lmx1a is expressed early in mDA progenitor 
cells and serves as an mDA progenitor marker in the VZ/PZ, Nurr1 is a marker for 
immature mDA neurons and TH is a marker for mature mDA neurons. (d) 
Transcriptional control in mDA progenitors expressing Otx2, Foxa1/2 and Lmx1a/b 
which then undergo early differentiation into immature mDA neurons while 
migrating into the IZ. Here they continue to express Foxa1/2 and Lmx1a/b that are 
required at multiple stages of mDA neuron development. Immature mDA neurons 
begin to express Nurr1 and Pitx3. Late differentiation step of immature mDA 
neurons occurs while they migrate into the MZ and here mature mDA neurons 
express in addition to previous markers, TH, VMAT and AADC.        
 
 
1.5.3 Maintenance & Survival of mDA neurons 
The expression of many of the genes implicated in the generation of mDA neurons 
are also maintained in the adult such as Foxa2, Lmx1a/b, En1/2 and Nurr1. Mutant 
analyses have revealed that apart from their role in the development of mDA neurons, 
these factors also play critical functions in the maintenance and survival of mature 
mDA neurons. Analysis of mice heterozygous for Foxa2, revealed late-onset mDA 
neuron degeneration resulting in motor impairments in these mice (Kittappa et al., 
2007). This study highlighted the role of Foxa2 in the maintenance and survival of 
mature mDA neurons. A recent study by Doucet-Beaupre et al., (2016) also 
demonstrated the role for Lmx1a/b genes in the survival of mature mDA neurons in 
adult mice via the regulation of mitochondrial functions that are independent from 
their early role in mDA neuron development. Inactivation of Lmx1a/b recapitulated 
cellular pathogenic features observed in PD including a-synuclein aggregation and 
degeneration of mDA neurons (Doucet-Beaupre et al., 2016). The underlying 
neurodegenerative mechanism caused by the loss of Lmx1a/b was mitochondrial 
dysfunction measured by compromised respiratory chain activity hence increased 
oxidative stress and mitochondrial DNA damage (Doucet-Beaupre et al., 2016).  
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In addition to Lmx1a/b, En1/2 genes also function in mDA neuron maintenance and 
survival via regulation of the sensitivity of these neurons to mitochondrial insult in a 
cell autonomous and gene-dosage dependent manner (Alavian et al., 2009). Alavian 
et al. (2009) analysed both homozygous and heterozygous En1/2 mutants. En1/2 
homozygous mice died at birth resulting in a complete loss of mDA neurons by mid-
gestation and an overall deletion of the midbrain and rostral hindbrain (Alavian et al., 
2009). Viable En1/2 heterozygous mice however survive but postnatally they exhibit 
a progressive degeneration of mDA neurons resulting in PD-like molecular hallmarks 
and behavioural abnormalities (Alavian et al., 2009). In these En1/2 mutants, cell 
death of mDA neurons occurs due to increased expression of the pan-neurotrophin 
receptor gene (p75NTR) and a reduction of extracellular-signal-regulated kinase 1/2 
(Erk1/2) activity (Alavian et al., 2009). Due to these effects, Engrailed expression is 
also reduced and mitochondrial stability is compromised by inhibition of the anti-
apoptotic members of the Bcl-2 protein family (Alavian et al., 2009). 
 
Late functions of Nurr1 in the maintenance of maturing and mature mDA neurons of 
adult mice were also studied by conditional targeting of the Nurr1 gene in mice 
(Kadkhodaei et al., 2009). Conditional Nurr1 mice allowed for controlling the ablation 
of Nurr1 in either (i) late stage of mDA neuron development, while the mDA neurons 
are transitioning from their immature to mature stage, by using cNurr1DATCre mice 
(generated by crossing conditional Nurr1 mice with Cre under the control of DAT 
(DATCre) mice) and (ii) in the adult brain once the mDA neurons have already 
acquired their mature state by using transduction of adeno-associated virus (AAV) 
Cre-encoding vectors (cNurr1AAVCre) (Kadkhodaei et al., 2009).   
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During mDA maturation, analysis of cNurr1DATCre revealed a rapid loss of striatal 
dopamine content, sudden loss of mDA neuron marker expression and degeneration 
of mDA neurons (Kadkhodaei et al., 2009).  
Inactivation of Nurr1 in already matured mDA neurons in adult cNurr1AAVCre-
injected mouse brains however revealed a more progressive and slower loss striatal 
DA and reduction in mDA neuron marker expression (Kadkhodaei et al., 2009). 
Together, these results suggest the additional crucial and important roles for 
developmental transcription factors in terminally differentiated mature mDA neurons 
in the maintenance of their mDA properties, mitochondrial functions and ultimately 
their survival.  
 
The paired-like homeodomain transcription factor 3 (Pitx3) belongs to the RIEG/PITX 
homeobox family, is expressed in post-mitotic mDA neurons which is maintained into 
adulthood (Smidt et al., 1997). Despite, Pitx3 expression in all mDA neurons, the 
SNc and VTA subpopulations have differential requirements for Pitx3 function 
(Maxwell et al., 2005). Overexpression studies of Pitx3 in human non-neuronal and 
mouse embryonic stem cell lines demonstrated Pitx3’s ability to induce endogenous 
expression of TH (Messmer et al., 2007). Further evidence to support the 
requirement for Pitx3 in mDA neuronal survival is from the analysis of the naturally 
occurring Pitx3 mutant mice known as the ‘aphakia’ mouse. This mouse model has 
two 5’ deletions in the Pitx3 gene (Rieger et al., 2001). These Pitx3ak/ak mice display 
significant reduction of mDA axons in the dorsal striatum (Nunes et al., 2003) and 
present with motor impairments due to a significant loss of mDA neurons in the SNc 
(Hwang et al., 2003). Analysis of transgenic Pitx3-GFP knock-in mice, in which the 
entire Pitx3 coding sequence is replaced with the green fluorescent protein (GFP) 
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reporter under the control of the Pitx3 promoter, revealed that selective loss of SNc 
neurons compared to the VTA is due to the dependency for Pitx3- induced TH 
expression in SNc neurons but not in VTA neurons (Maxwell et al., 2005). Since at 
E12.5, Pitx3 expression in laterally positioned early SNc immature mDA neurons is 
initiated before the onset of TH expression (Maxwell et al., 2005). In contrast, 
medially positioned VTA immature mDA neurons already expressed TH ahead of 
Pitx3 expression suggesting that TH expression is not induced by Pitx3 in this 
subpopulation (Maxwell et al., 2005).  
In addition to inducing the expression of TH exclusively in SNc mDA neurons 
(Messmer et al., 2007; Maxwell et al., 2005), Pitx3 regulates other downstream 
targets within SNc neurons including the neurotrophic factors BDNF and GDNF 
(Peng et al., 2011) and the gene encoding the enzyme ALDH1A1 (Chung et al., 
2005b). Together, these results highlight the role of PITX3 in the survival of SNc 
subpopulation of mDA neurons while also highlighting the heterogeneity of mDA 
neurons and their requirements for different transcription factor proteins.  
 
Besides these broadly expressed genes that are expressed in mDA neurons in early 
development and in mature mDA neurons, the survival of post-mitotic, terminally 
differentiated, mature mDA neurons is further controlled at a more subset-specific 
level. Specific genes are expressed less broadly and more specifically in only a 
porportional ‘subset’ of mDA neurons compared to the entire population, this can 
include either SNc-specific or VTA-specific subsets, ranging from 95% of each of the 
SNc or VTA subpopulations or down to less than 10% of the mDA domain. Subset-
specific genes may not only be required for mDA survival but may also be important 
for the correct circuitry and topography of mDA neurons. In light of this, heterogeneity 
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of mDA neurons is highly complex and other factors that are important for the survival 
of mDA neurons, specifically VTA-specific subsets include Otx2, Calbindin, Aldh1a1 
(see later) and Neurod6, which is the subject of this thesis. 
 
1.6 Heterogeneity of mDA neurons 
 
1.6.1 mDA cell anatomical location & morphology 
Histofluorescence techniques have identified the anatomical mapping and 
localisation of mDA neurons. This historical experimental approach has traditionally 
divided mDA neurons in to three distinct subpopulations; the lateral A9 SNc mDA 
neurons and the mDA neurons of the medial A10 VTA (Figure 1-2b) as well as A8 
RRF mDA neurons (Figure 1-2a). Majority of mDA neurons lie within these regions 
but small numbers of mDA neurons are also localised to the substantia nigra pars 
reticulata (SNr) and substantia nigra pars lateralis (SNl; Bjorklund and Dunnet, 2007).  
SNc neurons are also further sub-divided into a dorsal and ventral tier according to 
their cell morphology and connectivity pattern. Dorsal tier SNc neurons have a 
rounded and fusiform shape, and exhibit relatively low expression of dopamine 
transporter (DAT). SNc neurons of the ventral tier are form a densely packed sheet. 
These are more angular in shape, are calbindin-negative, have higher DAT 
expression levels and express the G-protein coupled inwardly rectifying K channel 2 
(GIRK2) ion channel protein (Bjorklund and Dunnet, 2007). VTA-specific mDA 
neurons are localised within the interfascicular nucleus (IF), paranigral nucleus (PN), 
and parabrachial nucleus (PBP); Figure 4-1I). 
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Figure 1-5 Heterogeneity of mDA neurons in the ventral midbrain and their 
projection pathways in the forebrain of rat (cited from Bjorklund and Dunnett, 
2007).  
(a) The anatomical location of mDA neurons that send their axons along the 
mesostriatal pathway is mainly within the SNc and innervate the caudate-putamen 
of the dorsal striatum. This pathway also consists of mDA neurons in the VTA that 
innervate the ventral nucleus accumbens (NAc) regions, (b) mDA neurons that 
project their axons along the mesolimbic pathway have their cells of origin 
intermixed mainly within VTA regions and these innervate the amygdala (Amg), 
olfactory tubercle (OT) and the lateral septum (LS), (c) mDA neurons that project 
their axons along the mesocortical pathway have their cells of origin intermixed 
between SNc and VTA subpopulations and innervate the prefrontal (PFC), 
entorhinal and cingulate cortices. mesocortical pathways in the rat. VTA, ventral 
tegmental area; SNc, substantia nigra pars compacta, SNr, substantia nigra pars 
reticulate; SNl, substantia nigra pars lateralis. 
 
 
 
1.6.2 mDA axonal targets in the forebrain 
Tracing studies have also subgrouped these mDA neurons according to their axonal 
projections along three distinct projection pathways that innervate distinct target 
areas in the forebrain, each correlating to specific functions.  
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The A9-SN mDA neurons project along a nigro-striatal pathway to target the caudate 
putamen of the dorsal striatum. The A10-VTA mDA neurons project via the 
mesocortical pathway to the cortex (cingulate, prefrontal and perirhinal cortices) and 
mesolimbic pathways to innervate various limbic structures including the amygdala, 
olfactory tubercle and the septum. In addition to these targets, the A10 VTA mDA 
neurons also target the nucleus accumbens of the ventral striatum (Bjorklund and 
Dunnett, 2007). The anatomical location of the mDA neurons and their projection 
pathways to forebrain target areas have been summarised in Figure 1-5. Single-cell 
tracing of long- range projections neurons have divided mDA neurons of the VTA 
that terminate their axons in the forebrain into four main subtypes (Aransay et al., 
2015). These are the (i) mesocorticolimbic; that project to both neocortex and basal 
forebrain, (ii) mesocortical; projecting exclusively to the neocortex, (iii) mesostriatal; 
terminating only in the caudate putamen of the striatum and (iv) mesolimbic; that 
project their mDA axons to the NAc and basal forebrain including lateral septal 
regions (Aransay et al., 2015).    
 
1.6.2.1 Lateral Septum as a target of mDA neurons 
In the subcortical forebrain, the lateral septum (LS), also sometimes referred to as 
the lateral septal nucleus (LSN), is anatomically located dorso-caudally to the 
nucleus accumbens and dorso-rostrally to the decussation of the anterior 
commissure and the hypothalamus (Sheehan et al., 2004). In rodents, the LS is 
located directly between the lateral ventricles (Sheehan et al., 2004). Like the 
midbrain, the LS is also considered to be a very heterogenous structure in regards 
to its cellular organisation, neurochemical properties, dynamic range of efferents and 
afferent connections to several other brain regions.  
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1.6.2.1.1 LS Anatomical Organisation 
Swanson and Cowan, (1979), Verney et al., (1987) and several others since have 
regionally divided the LS into its cytoarchitectonic subdivisions with their dorsal (LSd/ 
DLS/ LSNd), intermediate (LSi/ ILS/ LSNi) and ventral (LSv/ VLS/ LSNv) components 
(Swanson and Cowan, 1979; Verney et al., 1987; Sheehan et al., 2004). For the 
purpose of this work and simplicity, the LS components will be referred to in this work 
and resuming chapters as dorsal (LSd), intermediate (LSi) and ventral (LSv) as 
shown in Figure 1-6. Swanson and Cowan (1979) have detailed the definitions of 
these LS components clearly as follows: 
 
LSd - “The dorsal part of the lateral septal nucleus is triangular in outline when seen 
in frontal sections; it lies immediately ventral to the angle between the corpus 
callosum and the lateral ventricle… The dorsal part of the lateral septal nucleus, as 
we have defined it, corresponds to the nucleus dorsalis pars externa of Andy and 
Stephan (1964).”  (Swanson and Cowan, 1979) 
LSi – “The intermediate part of the lateral septal nucleus is the largest and most 
heterogeneous subdivision of the lateral septal nucleus. The neurons of the inter- 
mediate division become more widely scat- tered as one approaches the medial 
septal nu- cleus, from which they are separated by the fibers of Zukerkandl's bundle.” 
(Swanson and Cowan, 1979) 
LSv – “A distinct ventral part of the lateral septal nucleus has been recognized in a 
number of species… It is separated ventrolaterally from the bed nucleus of the stria 
terminalis by a cell-free zona limitans.” (Swanson and Cowan, 1979). 
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Figure 1-6 The subdivisions of the lateral septum and DA innervations in LS 
regions 
A, The LS is subdivided into dorsal (LSd), intermediate (LSi) and ventral (LSv) 
regions. B, Antibody immunohistochemistry for TH reveals DA axons innervating 
both LSd and LSi components (white staining) in adult mouse brain. Cc, corpus 
callosom; LSd, dorsal lateral septum; LSi, intermediate lateral septum; LSv, ventral 
lateral septum; MS, medial septum; TH, tyrosine hydroxylase. 
 
   
1.6.2.1.2 LS Neuronal Subtypes  
The adult septum which includes the lateral (LS), medial (MS) and ventral (VS) septal 
nuclei is described as an ‘onion-like’ structure according to the distribution of 
neuronal marker expression in distinct subsets of septal neurons (Wei et al., 2012). 
Septal neurons are primarily GABAergic however a proportion of MS neurons are 
also cholinergic. Like mDA neurons, septal neurons are also extremely 
heterogenous; they are generated in development in an “outside-in” pattern giving 
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rise to five main subtypes (Wei et al., 2012). These consist of (i) parvalbumin PV+ 
GABAergic, (ii) choline acetyltransferase ChAT+ cholinergic, (iii) neuronal nitric oxide 
synthase nNOS+, (iv) calretinin CR+ GABAergic and (v) calbindin CB+ GABAergic 
neurons, which are distributed from ventral- medial to dorsal-lateral positions 
diagonal ‘onion-like’ strips along the septum (Wei et al., 2012). Of these neuronal 
subtypes, LS neurons however consist of GABAergic neurons. The LSi neurons 
express calbindin (CB-immunoreactive) and the LSv neurons express calretinin (CR-
immunoreactive) as neuronal markers.  
 
1.6.2.1.3 LS Connectivity  
The LS sends efferent output to a wide range of brain regions and also receives 
abundant afferent glutametergic inputs from the hippocampus. Additionally, those 
brain regions associated with the regulation of emotional states including the 
amygdala, medial prefrontal cortex, bed nucleus of the stria terminalis and entorhinal 
cortex also send afferent projections to the LS. Brain areas that control motivational 
responses such as hypothalamic and midbrain regions also send afferents to 
integrate connections within the LS. Of the midbrain regions, the LS receives inputs 
from the locus cerulus, raphe nucleus, dorsal tegmentum (Cornwall et al., 1990) and 
VTA which send their adrenergic, serotonergic, cholinergic and dopaminergic 
(Gaspar et al., 1985) projections respectively.  
 
1.6.2.1.3.1 DA axons terminating in LS 
The regulation of autonomic, endocrine and behavioural responses to stressful 
environmental circumstances are primarily mediated by the involvement of mDA 
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axon projections to the LS and BNST (Sesack, 2002; Lindvall and Stenevi, 1978). 
The LS receives DA innervation from VTA, these make direct synaptic contact with 
perikarya and dendrites of septal neurons (Gaspar et al., 1985). These connections 
produce both excitatory (Assaf and Miller, 1977) and inhibitory postsynaptic 
responses. Several studies throughout the 1970s and 1980s have reported the 
identification of dopaminergic fibers by observations of DA/ TH immunoreactivity in 
more than one components of the LS in discrete axonal arrangements. 
 
Two distinct types of DA axon fibers were observed within the LS as described by 
Lindvall in 1974. One DA fiber type observed in the LS was of spherical spindle-like 
shape that was regularly spaced with fine varicosities (Lindvall, 1975). These fibers 
had intervaricose segments that were difficult to visualise (Lindvall, 1975). In contrast, 
the second DA fiber type observed in the LS was clearly visible as smooth fibers 
without many varicosities (Lindvall, 1975). Furthermore, this DA axon type was often 
seen outlining unlabelled non-fluorescent neuronal cell bodies and proximal 
dendrites of the LS and formed pericellular arrangements (Lindvall, 1975).  
Ultrastructural analysis of DA fibers by immunocytochemistry using the peroxidase 
method and anti-DA antibodies in LS regions was also investigated by Onteniente et 
al., (1984). Onteniente et al., (1984) described the DA axons that innervate along the 
LSi region as “packed in a band incurving from the border of the lateral ventricle to 
the medial part of the lateral septum” (Onteniente et al., 1984). These DA axons were 
observed along the entire rostro-caudal extent of the LS (Onteniente et al., 1984; 
Lindvall, 1975).  
According to Lindvall and Stenevi (1978), the fully developed adult LS contained DA 
axons along four longitudinal fields or strips along its rostro-caudal extent. One DA 
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strip in rostral LS, two main DA strips along the medial and lateral extent of the middle 
septum and one last DA strip in caudal LS. Describing the two main DA strips of the 
medial and lateral portions of the middle septum, Lindvall and Stenevi (1978) identify 
dopaminergic innervations to the lateral septal area observed in rat as one that 
originates from the medial part of the A10 mDA cell group of the VTA (Lindvall and 
Stenevi, 1978). Specifically, DA axons from the VTA form two distinct terminal 
patterns in the LS, one that is smooth forming pericellular arrangements around LS 
cells (Lindvall and Stenevi, 1978; Lindvall, 1975). This DA axon type is  observed in 
both LSi and appears scattered in LSd regions (Lindvall, 1975). The second type of 
DA axons that form fine-varicose axons into a dense band sheet around the fornix 
are found within the LSi region, and also have their cells of origin in the VTA (Lindvall 
and Stenevi, 1978).   
Despite these observations, detailed molecular and cellular characterisations of the 
VTA-specific mDA cells of origin that project their axons to the LS have not been 
thoroughly documented. Although several lesion studies (Lindvall, 1975), LS-injected 
horseradish peroxidase (HRP) retrograde labelling (Assaf and Miller, 1977; Lindvall 
et al., 1977; Carter and Fibiger, 1977; Fallon and Moore, 1978) and autoradiographic 
anterograde (Fallon and Moore, 1978) studies have shown the overall distribution of 
mDA cells in the VTA that project to the LS, detailed molecular characterisation of 
these septal-projecting VTA-specific mDA neurons, such as specific molecular 
markers, or factors important for the survival and correct axonal targeting to this 
region have not been investigated.  
 
Although DA innervations have been visualised in the LS, one of the VTA nuclei 
implicated in direct projection to the LS is the PN of the VTA (Aransay et al., 2015). 
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All PN mDA neurons are mesolimbic in the sense that they send axons only to limbic 
forebrain targets (Aransay et al., 2015). Furthermore, whether mDA projections to 
the LS are exclusive or whether these axons project collaterals to additional target 
areas within the forebrain is not clear.  
Single-cell axon tracing of long-range projection neurons of the VTA by transfection 
of the Sindbis-pal-eGFP vector in mice combined with axon labelling with 
iontophoretic microdeposits of biotinylated dextran amine (BDA) and reconstruction 
of individual axonal trees from serial sections, revealed two individual neurons of the 
PN in the VTA that projected axons exclusively to the LS (Aransay et al., 2015). 
However, one mDA neuron from the PN projecting to the LS, terminal arbor in the 
LS measuring 10.7mm, also displayed axonal branching to the NAc (Aransay et al., 
2015). These findings support further heterogeneity of mDA neurons projecting to 
forebrain structures and the molecular mDA subset projecting to the LS still need to 
be investigated in detail. Furthermore, molecular markers need to be identified that 
can label functional mDA neurons projecting to LS regions.    
 
 
1.6.2.1.4 LS Functions 
The lateral septum with its connections to several other brain regions, is implicated 
in many behaviours. However, the specific activation of DA neurotransmission in LS 
and the behavioural functions of LS functioning in a dopamine context have been 
studied in a limited number of studies implicating this circuit in the modulation of the 
septo-hippocampal pathway (Robinson et al., 1979), learning (Yamamuro et al., 
1995), sensory-related processing related to stress (Adams and Moghaddam, 2000) 
and drug addictive behaviours. Particularly, the actions of amphetamine (Renard et 
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al., 2014), cocaine (Sotomayor-Zarate et al., 2013; Reddy et al., 2016; Harasta et al., 
2015) and alcohol (Jonsson et al., 2015) as drugs of abuse on DA elevation, release 
and uptake within the LS have been investigated to date.  
 
Renard et al., (2014), investigated the withdrawal effects of chronic amphetamine 
(AMPH) on inducing changes in DA transmission within the LS. Male Sprague- 
Dawley rats were injected with AMPH over 14 days and then subjected to withdrawal 
periods ranging from 24 hours to 14 days. AMPH-treated rats displayed significantly 
reduced potassium (K+)-induced release of extracellular DA levels in the LS 
measured by in vivo microdialysis after 14 days of AMPH withdrawal compared to 
saline-treated controls (Renard et al., 2014). No changes were observed however in 
DA tissue content or TH expression levels although VMAT levels were significantly 
lower after 14 days of AMPH withdrawal of AMPH-treated rats compared to saline-
treated controls. This study was the first to demonstrate changes in K+-induced DA 
release in the LS resulting directly from withdrawal after repeated AMPH 
administration (Renard et al., 2014). The results also provide a link in reduced DA 
releasability as a result of reduced DA vesicular uptake and implicate AMPH 
abstinence syndrome in the role of DA afferents within the LS.  
 
Functional properties of DA innervations of the LS were also investigated by 
assessing action-potential mediated DA release in LS using microdialysis after 
subjecting male Sprague-Dawley rats to handling, which is a form of mild stress for 
these otherwise calm rat breed (Adams and Moghaddam, 2000). Once septal 
baseline DA levels were established, animals were handled in their cage and 
subjected to restraining of their movement in the cage for 20 minutes. During this 
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period, septal extracellular DA levels significantly increased to 140% of baseline DA 
in response to handling (Adams and Moghaddam, 2000). DA levels remained this 
high in the LS an hour after handling and only normalised to basal DA state 80 
minutes after termination of handling (Adams and Moghaddam, 2000). After DA 
levels returned to basal pre-stress levels, local application of the sodium channel 
blocker, TTX, through the microdialysis probe produced significant decline in DA 
levels below detection demonstrating that previously measured DA was of neuronal 
origin (Adams and Moghaddam, 2000). This study implicates functions of DA 
innervation within the LS to sensory information processing of stress.  
 
Glucagon-like peptide 1 receptor (GLP-1R) is expressed at peak mRNA levels in the 
LSd portion of the LS. The LSd is an anatomical site that has a crucial function in 
reward perception. Functional relevance of GLP-1R expression within the LSd is in 
driving behavioural responses to cocaine due to increased excitability of these cells 
in whole-cell patch-clamp recording as a result of genetic ablation of Glp-1r (Harasta 
et al., 2015).  
Another study links GLP-1R-mediated regulation of the cocaine action with DA 
homeostasis within the LS (Reddy et al., 2016). DA terminals, visualised by DAT 
staining within the LSi, were found to be positioned adjacent to GLP-1R- expressing 
cells within the dorso-medial aspect of the LSi in both rostral and caudal LS sections 
of mApple BAC transgenic mice under the control of the GLP-1R promoter (Reddy 
et al., 2016). Furthermore, cocaine administration via the microdialysis probe 
increased septal extracellular DA levels by ~5 fold and systemic administration of a 
GLP-1R agonist Exendin-4 was able to prevent this rise in extracellular DA in reduce 
c-fos expression within the LS (Reddy et al., 2016). In addition to systemic, local 
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activation of GLP-1R, by co-perfusing the GLP-1R agonist Exendin-4 and cocaine 
via microdialysis probes, also blocked cocaine-induced elevation of extracellular DA 
levels. Hence septal neuropeptide GLP-1R signalling modulates cocaine’s ability to 
elevate DA by promoting an increase in DAT expression within the LS thereby 
increasing DA uptake (Reddy et al., 2016).  
 
Although these studies have provided with some insights into DA effects on the LS, 
the direct function of the DA afferents from the VTA to the LS have not been fully 
elucidated and the functional relevance of this brain pathway in terms of behaviour 
has not been clearly determined.  
 
1.6.3 mDA neuronal functions & disease 
The A9-SN mDA neurons function in regulating motor control and movement thus 
the specific loss and degeneration of these neurons, particularly of the SNpc, is the 
underlying pathological hallmark of PD. The resulting loss of SN mDA neurons 
results in clinical symptoms of PD related to motor impairment including gait 
disturbance, resting tremor, bradykinesia and rigidity.   
The mesocortical and mesolimbic pathways include projections from the A10-VTA 
and A8-RRF to their relative targets, collectively function to regulate emotional 
behaviour, cognition, memory, learning and reward mechanisms (Tzschentke and 
Schmidt, 2000; Ang, 2006). Dysfunction of these pathways are implicated in 
depression (Dailly et al., 2004), psychotic symptoms in schizophrenia (Sesack and 
Carr, 2002), attention-deficit hyperactivity disorder (ADHD; Bjorklund and Dunnet, 
2007; Lammel et al., 2008) and drug addiction (Kelley and Berridge, 2002; Wightman 
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and Robinson, 2002).  
1.6.4 Electrophysiological phenotypes & circuitry/inputs 
DA neurons also exhibit difference in the kind of information they integrate and their 
electrophysiological output firing patterns. SN mDA neurons that project along the 
mesostriatal pathway, exhibit a typical action potential (AP) waveform with a slow 
regular discharge pattern with prominent afterhyperpolarisations (AHPs) and sag 
components (Lammel et al., 2008). VTA mDA neurons that project along 
mesocortical pathways exhibit a broad AP waveform with a smaller amplitude and 
these APs have smaller maximal depolarization and repolarisation speeds (Lammel 
et al., 2008). The discharge pattern is fast and regular, without any AHPs and sag 
components (Lammel et al., 2008). This study highlighted the two distinctive 
functional phenotypes of the SN and VTA mDA neurons. 
 
mDA neurons can also be further categorised into two distinct types according to 
their response to aversive stimuli. An aversive stimulus can be defined as any 
negative stimulus with undesirable consequences. SN-mDA neurons are mainly 
saliency coding, which are activated in response to aversive events. In contrast, 
VTA-mDA neurons are reward-value coding which are inhibited by aversive stimuli 
(Matsumoto and Hikosaka, 2007; Bromberg-Martin et al., 2010; Watabe-Uchida et 
al., 2012).  
The whole brain mapping study of the direct monosynaptic inputs to the SN and VTA 
mDA areas conducted by Watabe-Uchida et al., (2012) using the rabies virus 
provided an insight into these differences in saliency and value coding of mDA 
neurons. This difference was attributed to them receiving different excitatory inputs; 
SN-mDA neurons from the subthalamic nucleus and the somatosensory/ motor 
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cortex in contrast to the VTA-mDA neurons from the lateral hypothalamus (Watabe-
Uchida et al., 2012). Besides this, the study highlighted the diversity of areas from 
which information is integrated by synaptic input to mDA neurons of both the SN and 
VTA, including inputs from the septum to VTA (Watabe-Uchida et al., 2012).  
 
1.6.5 mDA subsets 
Specific recent studies have now suggested that mDA neurons within each sub-
population also represent heterogenous and mixed subsets. Microarray based gene 
profiling of the A9-SN and A10-VTA specific subpopulations by laser capture 
microdissection (LCM) techniques, revealed a number of transcription factors that 
are preferentially expressed in either the SNc or the VTA including those only 
expressed in small subsets (Chung et al., 2005a). SNc-specific mDA subsets include 
Sox6 (Panman et al., 2014) amongst several others (Chung et al., 2005a). VTA-
specific mDA subsets include orthodenticle homeobox 2 (Otx2; Di Salvio et al., 2010), 
Calbindin D28K (Liang et al., 1996a), aldehyde dehydrogenase family 1 (Aldh1a1/ 
Raldh1; Chung et al., 2005ab; Jacobs et al., 2007), Nolz1 (Panman et al., 2014) and 
neurogenic differentiation factor-6 (NeuroD6).  
 
1.6.5.1 SNc-specific mDA subsets 
1.6.5.1.1 Sox6  
An SNc specific marker is the transcription factor Sox6, which was identified in a 
screen for mDA neuron-specific expressed genes (Panman et al., 2011). In the 
cortex, Sox6 is important for interneuron subtype diversity (Azim et al., 2009; Batista-
Brito et al., 2009). Sox6 expression was investigated in the ventral midbrain by 
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immunohistochemistry at embryonic E18.5 and adult stages by Panman et al., 2014.  
At E18.5, Sox6 protein expression was localised in post-mitotic mDA neurons of the 
lateral SNc TH+ mDA subpopulation and corresponded to 95% of the total SNc mDA 
neurons that co-expressed TH and Sox6 and later in the adult Sox6+ accounted for 
85% of the total SNc TH+ mDA subpopulation (Panman et al., 2014). Further 
characterisation of the Sox6+ mDA subset with additional molecular markers 
confirmed the status of Sox6 as an SNc-specific mDA subset marker since Sox6+ 
mDA neurons co-localised with SNc markers Girk2 and glycoDAT. Raldh1 is a 
marker for a proportion of both the ventral SNc and VTA mDA neurons. The Sox6 
mDA subset localised in the SNc, also co-localised with the SNc compartment of 
Raldh1 expressing mDA subpopulation but not the VTA in both embryonic E18.5 and 
adult ventral midbrain. In support of Sox6 being an SNc- specific mDA subset and 
an SNc- specific molecular marker, Sox6+ mDA neurons do not co-express any VTA 
molecular markers including Otx2 and Calbindin, which are both absent from the 
Sox6 subpopulation in both embryonic and adult Sox6+ mDA subset. After molecular 
characterisation of the Sox6 population, the study identified the dorsal- lateral 
striatum as the specific projection target site of Sox6+ mDA neurons in the SNc 
(Panman et al., 2014). This was demonstrated by retrograde tracing experiments 
using fluorgold injected into the dorsal striatum, which retrograde labelled majority of 
the Sox6+ mDA neurons in the SNc in the adult brain (Panman et al., 2014).  
 
During the early development of mDA neurons, at E11.5, Sox6 expression is 
confined to the medial portion of Corin+ Lmx1a+ mDA progenitors where they also 
express low weak levels of Otx2 but do not express Nolz1. This subset is referred to 
as the Sox6+/Otx2+weak/Nolz1- subpopulation of mDA progenitors already 
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established at E11.5 and later becomes the lateral SNc (Panman et al., 2014). Sox6 
is then continued to be expressed in early post-mitotic immature Nurr1+/ TH- mDA 
neurons. Between E13.5 and E18.5, differentiating post-mitotic Sox6+ mDA neurons 
are found medially in the IZ of the mDA domain and these Sox6+ mDA cells first 
migrate ventrally and then extend laterally along the MZ and form the lateral SNc 
subpopulation of mature mDA neurons (Panman et al., 2014). Functionally, Sox6 
may regulate the expression of axon guidance molecules required for correct 
innervation to the dorsal-lateral striatum and for the maintenance of SNc-like mDA 
properties since the loss of Sox6 causes a reduction in mDA axonal innervations 
within the doral lateral portion of the striatum in Sox6 mutants (Panman et al., 2014).  
Sox6 is also expressed in human neuromelanin- containing SNc mDA neurons and 
Sox6 levels are significantly diminished in patients with PD compared to control 
individuals as measured by densitometry of Sox6-expressing neuromelanin-
containing mDA neurons (Panman et al., 2014). These findings implicate Sox6+ SNc 
neurons as a functional mDA subset and implicate Sox6 in the maintenance of SNc-
like properties of mDA neurons and PD.  
 
1.6.5.2 VTA-specific mDA subsets 
1.6.5.2.1 Otx2  
The important roles of Otx2 in early stages of mDA neural development are well 
known. Otx2 is expressed in mDA progenitors cells as early as embryonic day (E) 9 
(Ang et al., 1994). Otx2 is required for determining the molecular code and 
specification of mDA progenitors by regulating the extent, identity and fate of the 
mDA progenitor domain in the ventral midbrain (Puelles et al., 2003; 2004) and mDA 
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neurogenesis (Vernay et al., 2005). For the early stage functions of Otx2 in mDA 
progenitor specification, see reviews (Smidt and Burbach et al., 2007; Ang, 2006).  
1.6.5.2.1.1 VTA-specific expression of Otx2 
In addition to its expression and function in progenitor specification, from E12.5, Otx2 
is also expressed by a subset of post-mitotic embryonic TH+ mDA neurons that are 
fated to generate VTA-specific mature mDA neurons (Di Salvio et al., 2010a). At 
E15.5 and E18.5, Otx2+/TH+ double positive cells continue to increase along the 
rostral-caudal extent of the VTA, whilst there is no expression of Otx2 in the SN (Di 
Salvio et al., 2010a). In the adult, there is graded expression Otx2 in TH+ neurons 
along the dorso-ventral VTA. In the dorsal VTA, very low numbers of TH+ neurons 
(8%) co-localise with Otx2, whereas Otx2 expression is maintained in a high 
percentage of TH+ mDA neurons localized in the central (medial tier) (37%) and 
ventral (75%) VTA (Di Salvio et al., 2010a). An LCM approach was used by Chung 
et al., 2005, 2010 to isolate VTA and SN mDA neurons and showed Otx2 mRNA 
levels to be elevated by up to 6 fold in the VTA compared to the SN of the adult 
mouse (Chung et al., 2005; Chung et al., 2010) and human (Chung et al., 2010).  
 
1.6.5.2.1.2 VTA-specific functions of Otx2 
1.6.5.2.1.2.1 Subtype identity  
Using a Cre mutant mouse model to study the function of Otx2 in adult mDA VTA 
neurons, Di Salvio et al., 2010b found that Otx2 functions to control molecular 
subtype identity of central VTA neurons by restricting the expression of Girk2, to the 
dorsal-lateral VTA neurons instead of central VTA neurons.  
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1.6.5.2.1.2.2 Projection targeting 
To elucidate the role of Otx2 in regulating the axonal projection patterns of VTA mDA 
neurons, Chung et al., 2010 validated potential candidate transcriptional targets from 
their previous microarray study (Chung et al., 2005a). Overexpression, using 
lentivirus encoding Otx2, and endogenous reduction of Otx2, using short hairpin RNA 
(shRNA) directed against Otx2, in MN9D cells and/or ventral mesencephalic cultures, 
revealed that in the VTA, Otx2 is required for the upregulation of axon guidance 
molecules including Neuropilin 1 (Npn1), Neuropilin 2 (Npn2) and Slit2 (Chung et al., 
2010).  
Subsequent analysis of adult Otx2 conditional knockout (cKO) mice, that were 
previously reported to display a significant reduction in both VTA and SN mDA 
neurons due to the loss of Otx2 expression (Borgkvist et al., 2006), revealed a 
dramatic reduction in VTA mDA neurons in nearly all VTA-specific target areas 
including the PFC, NAc, OT, amygdale and the septum (LS and dorsal; Chung et al., 
2010). Together, these results indicate the possible function of Otx2 in establishing 
correct projection targeting of VTA mDA neurons. Whether this is directly and 
independently of other transcription factors, and additional downstream targets, is 
still unclear.  
 
1.6.5.2.1.2.3 Neuroprotection 
Otx2 functions to modulate dopamine signaling by limiting the number of VTA TH+ 
mDA neurons with efficient reuptake of dopamine by restricting high expression 
levels of glycol-DAT to dorsal-lateral VTA Girk2+/TH+ neurons instead of central and 
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ventro-medial VTA mDA neurons (Di Salvio et al., 2010b) hence negatively 
regulating DAT expression. Since Otx2 negatively regulates DAT expression in VTA 
mDA neurons, Otx2 functions as a neuroprotective factor for VTA mDA neurons that 
express Otx2. This was analysed by assessing the sensitivity of VTA and SN-specific 
mDA subpopulations that express and do not express Otx2, respectively, to the 
neurotoxin MPTP. MPTP-treated Otx2 mutants displayed a significant reduction in 
GFP+/TH+ VTA neurons compared to control mice treated with MPTP, and showed 
a similar sensitivity to MPTP as wild-type SN mDA neurons. Since MPTP is a 
dopamine analog, it can be efficiently bound by glyco-DAT and so by negatively 
regulating DAT expression, Otx2 confers neuroprotection for the Otx2-expressing 
VTA mDA neurons. To confirm that the difference in increased susceptibility to 
MPTP-induced neurodegeneration of SN mDA neurons compared to that of the VTA, 
is largely due to the neuroprotective role of Otx2, ectopic expression of Otx2 in the 
SN showed an increase in the resistance of these SN mDA neurons upon MPTP 
treatment (Di Salvio et al., 2010b).  
The neuroprotective function of Otx2 was confirmed by an independent study by 
Chung et al., 2010 in which Otx2 was overexpressed in ventral mesencephalic 
cultures using lentivirus to validate putative transcriptional targets. Otx2 
overexpression revealed an upregulation of neuropeptides including vasoactive 
peptide (VIP) and adenylyl cyclase activating peptide (Adcyap; Chung et al., 2010). 
Treating ventral mesencephalic cultures with the MPP neurotoxin, after 
overexpression of Otx2 with lentivirus encoding Otx2, revealed a 25% increase in 
Otx2+/TH+ mDA neurons. Whereas reduction of Otx2 using shRNA, resulted in 25% 
decrease in Otx2+/TH+ mDA neurons. Since Otx2 regulates neuropeptides such as 
VIP and Adcyap, which are known to exhibit neuroprotective effects (Baranowska-
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Bik et al., 2013; Chung et al., 2005), the mechanism by which Otx2 expression 
renders VTA mDA neurons less susceptible to neurodegeneration is by upregulating 
neurotrophic and neuroprotective target genes (Chung et al., 2010).  
 
1.6.5.2.2 Calbindin D28K  
Majority of Otx2+ mDA neurons within the central and ventral VTA co-express 
Calbindin D28K (CB, Di Salvio et al., 2010a). CB is expressed in VTA neurons that 
are more resistant to neurodegeneration and thus has crucial neuroprotective 
functions (Mattson et al., 1991; German et al., 1992; Lavoie and Parent, 1991; Liang 
et al., 1996) by inhibiting apoptosis via the activation of the PI3-kinase-Akt signaling 
pathway (Sun et al., 2011). Further support for a pro-survival function and 
neuroprotective effects of CB are from the analysis of adult Pitx3-hypomorphic 
aphakia mice that have selective degeneration of SNc and dorsal VTA neurons that 
do not express CB (CB-negative mDA neurons; Luk et al., 2013).   
 
1.6.5.2.3 Nolz1  
Nolz1 is a zinc finger protein which is a member of the NET zinc finger protein family 
(Chang et al., 2013). It is important for neuron subtype diversification of striatal 
progenitor and post-mitotic differentiating neurons of the striatum (Chang et al., 
2013).  
In mature mDA neurons, Nolz1 is selectively expressed in VTA mDA neurons and 
not the SNc. Embryonically, Nolz1-expressing mDA neurons correspond to 18% of 
the total VTA mDA subpopulation at E18.5 and less than 10% of the VTA 
subpopulation in the adult ventral midbrain (Panman et al., 2014). 
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At E11.5, during the early development of mDA neurons at the progenitor stage, 
Nolz1 expression is in the laterally positioned mDA progenitors and these Nolz1+ 
mDA progenitors strongly co-express Otx2 yet are mutually exclusive to medially 
positioned Sox6-expressing mDA progenitors. Hence this lateral subpopulation is 
referred to as the Nolz1+/Otx2strong/Sox6- subpopulation of mDA progenitors, 
which later form a part of the medial VTA subpopulation providing evidence of an 
‘outside-in’ pattern of mDA neuron development (Panman et al., 2014). The function 
of Nolz1 in VTA neurons still remains to be determined.   
 
1.6.5.2.4 Aldh1a1 
Retinaldehyde dehydrogenase (Aldh1a) also known as Raldh1, is an enzyme that 
catalyses the oxidation of retinaldehyde into retinoic acid (RA). Aldh1a1 is expressed 
in mDA progenitor cells and the expression of this protein becomes restricted to a 
proportion of mDA neurons in the adult (Chung et al., 2005b). In mature mDA 
neurons, Aldh1a1 is expressed in a subset of both ventral SNc and ventral VTA 
subpopulations and its expression is regulated by Pitx3 in these neurons (Jacobs et 
al., 2007; Chung et al., 2005b). In the adult VTA, Otx2+ mDA cells account for 75% 
of TH+ neurons in the ventral VTA region. Aldh1a1 is expressed in all ventral Otx2+, 
Calbindin+ mDA cells of the VTA (Di Silvio et al., 2010). Aldh1a1 synthesises RA, 
which is neuroprotective for mDA neurons as demonstrated by treatment of Pitx3 
homozygous mutant mice with RA during mDA development resulting in SNc 
recovery by partial rescue of Aldh1a1 expression (Jacobs et al., 2007). The early 
role of Aldh1a1 in mDA progenitors remains to be determined however in adult VTA 
mDA neurons, Aldh1a1 also mediates the alternative non-canonical synthesis of 
GABA, independent from glutamate decarboxylase (GAD), facilitating the co-release 
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of GABA and DA from these ventral VTA neurons (Kim et al., 2015). This GABA co-
release is modulated by ethanol consumption at high binge-drinking alcohol 
concentrations. The functional relevance of diminished Aldh1a1 in this VTA subset 
leads to increased alcohol consumption implicating reward-based drug abuse and 
addictive behaviours (Kim et al., 2015).  
 
It is clear that VTA-specific mDA subsets are determined by the expression of 
key neuroprotective pro-survival molecular markers in dorsal, central and ventral 
tiers of the VTA. These represent distinct functional mDA subsets projecting to 
specific forebrain targets with unique roles in determining mDA circuitry and 
subsequently the modulation of specific DA behaviours. Evidence provided here has 
shed light on the molecular and functional heterogeneity of mDA neurons in the VTA. 
Since VTA mDA neurons and their vast axonal targets in the forebrain are implicated 
in several rewarding and aversive behaviours such as addiction and stress/ social 
sensory information processing, this complexity of mDA neurons needs to be 
unravelled in more detail at a more molecular level.  
  
1.7 bHLH Transcription Factors  
The family of basic helix-loop-helix (bHLH) transcription factors are crucial proteins 
that regulate many developmental pathways and comprise of more than 130 related 
and evolutionary conserved proteins in humans (Skinner et al., 2010). The number 
of bHLH genes increases with increasing complexity of organisms due to genetic 
duplications and phylogenetic diversification (Skinner et al., 2010; summarised in 
table 1-1; See appendix 7.2 for a list of human bHLH proteins). 
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Organism  Name  Number of bHLH genes 
Baker’s yeast  Saccharomyces cerevisiae  8 
Worm  Caenorhabditis elegans  39 
Fly  Drosophila melanogaster  58 
House mouse  Mus musculus  104 
Humans  Homo sapiens  125 
Table 1-1. Phylogenetic diversification. The number of bHLH genes increases with 
increasing complexity of organism. 
 
Murre et al., defined HLH proteins as “regulatory factors that when expressed in the 
appropriate cell type induce the expression of a number of genes, resulting in a 
tissue-specific phenotype.” (Murre et al., 1994).  
1.7.1 Structure of bHLH proteins 
The bHLH domain spans 60- 100 amino acids in length. A bHLH transcription factor 
protein can be structurally defined by its two primary domains; a basic region, which 
is required for its binding to DNA to a consensus DNA sequence (CANNTG) called 
the E-box sequence, and the helix-loop-helix domain, which is characterised by two 
a-helices separated by a loop (Bertrand et al., 2002). The HLH domain is required 
for dimerisation of the protein to form hetero- or homo-dimers (Lee, 1997).  
 
1.7.2 Classification of bHLH proteins  
The bHLH transcription factor proteins can be classified according to their spatial 
and temporal expression, specific properties, species of origin and phylogenetic 
homology (Murre et al., 1994). Classification by Murre et al., divides bHLH proteins 
into the following six broad classes I – VI (Murre et al., 1994).   
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Class I bHLH proteins are ubiquitously expressed and can form both hetero- and 
homodimers. These are mainly E-proteins including E12 (TCF3) and E2-2 (TCF4). 
These proteins generally act as transcriptional activators and are involved in the 
gene regulation of B cells, muscles and pancreatic tissues. 
The expression of bHLH proteins belonging to class II is restricted to specific 
tissues where they are able to control the expression of downstream genes in a 
tissue-specific manner and regulate cell-intrinsic differentiation by forming 
heterodimers with other ubiquitously expressed class I bHLH proteins. Class II is the 
largest class of bHLH proteins and consist of those that regulate muscle 
differentiation include Myogenin, MyoD and Myf-5. Of those expressed in the brain, 
class II bHLH protein families include the neurogenins, oligs and the NeuroD family.   
Class III bHLH proteins are involved in growth control and have important 
roles in cancer. Myc related proteins including c-Myc, L-Myc (Mycl1) and N-Myc 
(bHLHe37) belong to this class.  
Class IV consists of a very small group of bHLH factors that interact with Myc, 
including Mad and Max proteins. 
HLH proteins that represent class V are those that do not contain a basic 
region therefore lack their DNA binding domain and include the include Emc and Id 
proteins. They form non-functional heterodimers acting as competitive antagonists 
of other bHLH factors. 
  Class VI proteins are characterised by the presence of a proline amino acid 
residue in their basic region and have high homology to the Drosophila ‘Hairy and 
Enhancer of split’ protein for example, the negative regulator Hes5 which is the main 
effector in Delta-Notch signalling.   
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The Neurod1 and Neurod6 bHLH transcription factors, which are the focus of this 
work, belong to the large class II of bHLH proteins (Bertrand et al., 2002). According 
to this classification, they are able to heterodimerise with other class I and class V 
bHLH proteins. Importantly, both Neurod1 and Neurod6 are mainly expressed 
throughout the CNS. 
 
1.7.3 Neuronal bHLH transcription factor proteins in development 
Several bHLH transcription factors are expressed throughout the CNS and play 
important roles during neuronal development. They are broadly divided according to 
whether they act early- or late- during neuronal development as (i) determination 
factors or (ii) differentiation factors.  
 
Genes of determination factors are expressed early in embryogenesis and function 
in cell fate determination by initiating either glial or neuronal differentiation processes. 
They are expressed by multipotent progenitor and precursor cells in mitotic 
ventricular zones (VZ) of various brain regions. Since these factors are initiators of 
neuronal differentiation they are often termes as “proneural factors”. Examples of 
proneural determination bHLH factors are the Neurogenins (Ma et al., 1996) and 
Mash1 (Tomita et al., 2000).    
 
In contrast, differentiation factors are not expressed in progenitor cells and are 
absent from mitotic VZ regions of brain. They are expressed slightly later in 
embryogenesis in already determined cell fates and committed neurons and 
therefore are termed as “neuronal bHLH proteins”. Examples of neuronal bHLH 
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factors include those belonging to the NeuroD family, Neurod1, Neurod2 and 
Neurod6.    
 
Neuronal bHLH proteins, which include early determination factors and late-acting 
differentiation factors, can act as survival factors for the neurons in which they are 
expressed. In support of this, genetic inactivation studies of determination factors 
Ngn2/Mash1 for example, reveal a loss of neural progenitor cells (Andersson et al., 
2006a; Kele et al., 2006). Alternatively, inactivation of late-onset differentiation 
factors such as Neurod1/6 reveal a loss of terminally differentiating granule neurons 
of the hippocampus due to increased cell death (Schwab et al., 2000). In this thesis, 
inactivation of Neurod1 and Neurod6 will provide further evidence to support the 
survival properties of differentiation factors.  
 
 
1.8 NeuroD family of bHLH transcription factors 
 
The NeuroD subfamily of bHLH transcription factors include Neurod1 (Lee et al., 
1995), Neurod2 (Pleasure et al., 2000), Neurod4 (Tomita et al., 2000) and Neurod6 
(Schwab et al., 2000) named accordingly due to amino acid sequence similarity of 
the bHLH domain. In addition to this, the sequence homology between these NeuroD 
family members extends a further 40 amino acids beyond just the bHLH domain. 
This 40 amino acid sequence includes an atypical leucine repeat interspersed with 
proline residues (Lee, 1997). Importantly, all members of this gene family are “single-
exon-encoded-genes” (Lee, 1997). 
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According to Bertrand et al., (2002), the NeuroD family of bHLH proteins have 
characteristics of differentiation factors. Firstly, they are expressed in immature or 
mature neurons rather than in progenitor cells. Secondly, they possess the ability to 
promote neuronal differentiation when ectopically expressed (Lee et al., 1995).  
 
1.8.1 Neurod1 
Neuronal differentiation factor 1 (NEUROD1) also known as BETA2, BHF-1, MODY6, 
NeuroD and bHLHa3 was initially cloned by Lee et al., (1995) from a yeast two- 
hybrid protein interaction assay that investigated Neurod1’s ability to heterodimerise 
with a protein in Drosophila called Daughterless. The hamster homolog of Neurod1 
was also discovered by Naya et al., (1997). The Neurod gene maps to human 
chromosomal location of 2q32 and in mouse chromosome 2 (Tamimi et al., 1996). 
Generally, Neurod1 is highly expressed in regions where differentiating neurons 
reside and is expressed in many organs both within the PNS and CNS. In the PNS, 
Neurod1 is expressed transiently in the cranial and dorsal root ganglia (DRG) and 
otic vesicle. In the CNS, Neurod1 is expressed from around E11.5 and maintained 
into adulthood within the olfactory epithelium, olfactory bulb, retina, pineal gland, 
hippocampus, cerebellum and the cortex (Lee, 1997). Neurod1 expression is thought 
to be biphasic in the sense that one wave of expression is transient during 
neurogenesis, whilst a second wave of expression is in mature differentiated neurons 
(Lee, 1997).  
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1.8.1.1 Neurod1 Functions 
1.8.1.1.1 Cell fate specification & Neuronal differentiation 
Neurod1 has essential roles in cell fate specification and differentiation of subtypes 
of pancreatic islet cells (Chao et al., 2007). Analysis of Neurod1-null mice revealed 
a significant reduction in alpha and beta cells of the pancreas after E17.5 (Chao et 
al., 2007). Neurod1 is also required for the differentiation of granule cells in the 
hippocampus and cerebellum (Miyata et al., 1999). 
 
1.8.1.1.2 Cell survival  
Neurod1 is cell intrinsically required for the survival of mature and adult-born neurons 
of the hippocampus and olfactory bulb (Gao et al., 2009). Apart from the CNS, 
Neurod1 is essential for normal development of mammalian vestibular and auditory 
systems in the PNS (Liu et al., 2000; Jahan et al., 2010). Neurod1-null mutant mice 
exhibited behavioural impairments including reduced responses to sound, 
hyperactivity, circling behaviour and head tilting (Liu et al., 2000). Further analysis of 
these mutants revealed inner ear defects particularly a significant reduction in the 
number of sensory neurons in the cochlear-vestibular ganglion (CVG) between E13 
and E18.5 (Liu et al., 2000). At E13, cell quantification revealed a 30% and 40% 
reduction in cochlear and vestibular neurons, respectively. However, loss of CVG 
neurons became more severe during embryonic development and by E18.5 95% of 
cochlear and 85% of vestibular neurons were already lost in Neurod1 mutants 
compared to controls. Few remaining neurons survived until adulthood. The loss of 
CVG neurons in these mutants were further analysed to determine whether the loss 
is due to less proliferation of CVG to begin with or whether CVG neurons are lost 
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due to apoptotic cell death. Analysis of proliferative activity prior to neuron loss 
revealed by BrdU immunohistochemistry in these mutants showed proliferation was 
unaffected and the loss of CVG neurons in these mutants were as a result of delayed 
and defective delamination and increased apoptotic neuronal death (Liu et al., 2000) 
suggesting Neurod1 plays a major role in the maintenance and survival of post-
mitotic differentiating and terminally-differentiated neurons. Further studies on the 
mouse ear have also demonstrated Neurod1’s requirement in the survival and 
formation of axonal connections (Jahan et al., 2010). Conditional deletion of floxed 
Neurod1 was generated specifically for the ear using TgPax2-Cre mice and these 
were also compared with systemic Neurod1-null mice. These conditional Neurod1 
floxed mice survive after birth and in postnatal mice, Neurod1 is required for the 
survival of most spiral and vestibular neurons of the mouse ear and for axon 
projections of surviving cochlear afferents. In the absence of Neurod1, the axon 
connections of the surviving cells are disorganised (Jahan et al., 2010). Hence in 
addition to the fundamental role of Neurod1 in subtype-specific neuronal survival, 
Neurod1 is also crucial for the proper development of axon connectivity within the 
mammalian ear (Jahan et al., 2010).  
Neurod1 also controls tumour cell survival of neuroendocrine lung carcinomas and 
promotes metastasis via the regulation of downstream target genes; receptor 
tyrosine kinase B (TrkB), which is the receptor for brain-derived neurotrophic factor 
(BDNF) and neural cell adhesion molecule (NCAM) (Osborne et al., 2013).  
Neurod1 cKO mice under the control of cone- rod homeobox (Crx) allowed for the 
selective expression of Neurod1 specifically in the cone and rod photoreceptor cells 
of the retina (Ochocinska et al., 2012). Analysis of these mutants revealed the 
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requirement of Neurod1 also in the survival of retinal photoreceptors (Ochocinska et 
al., 2012).  
  
1.8.2 Neurod2 
The Neurod2 gene was mapped to chromosomal location 17q12 in human and 
chromosome 11 in mouse (Tamimi et al., 1997). Neurod2, also known as NDRF and 
bHLHa1, was first cloned and characterised by McCormick et al., (1996). Northern 
blot analysis detected Neurod2 expression from E11.5. Neurod2 expression levels 
peak shortly after birth and then declines to weaker expression levels (like Neurod6, 
see later; Schwab et al., 1998). Neurod2 expression is maintained in adulthood in 
regions of the CNS; cortical plate of the cortex, hippocampus, dendate gyrus and 
cerebellum (McCormick et al., 1996; Schwab et al., 1998). Since Neurod2 has a later 
onset of expression during embryogenesis and was found to activate the promoter 
of a more downstream gene, the GAP-43 gene (McCormick et al., 1996; like Neurod6, 
see later), Neurod2 is considered a downstream regulator of neurogenesis.   
 
1.8.2.1 Neurod2 Functions 
Neurod2 induces the neural differentiation of cortical projection neurons, mouse 
embryonic stem cells and is required for proper development of the amygdala 
(Bayam et al., 2015; Sugimoto et al., 2009; Messmer et al., 2012; Noda et al., 2006; 
Lin et al., 2005). In addition to neural differentiation, Neurod2 is essential for proper 
synaptic development of thalamocortical axons and patterning of the barrel cortex 
(Ince-Dunn et al., 2006). Neurod2-null mice, in which the entire Neurod2 coding 
region is replaced by b-galactosidase (Olson et al., 2001; Lin et al., 2004) were used 
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to observe Neurod2 expression and patterning defects. Neurod2-null mice exhibited 
a disorganisation and severe disruption of the cortical barrel field as revealed by 
antibody staining for mitochondrial cytochrome oxidase in thalamo-cortical axon 
terminals (Ince-Dunn et al., 2006). Lipophilic DiI labelling revealed that in the 
absence of Neurod2, these thalamo-cortical axons fail to segregate (Ince-Dunn et al., 
2006). Neurod2 is also required for the correct development and maturation of 
thalamo-cortical synaptic connections (Ince-Dunn et al., 2006). Neurod2-null mice 
lack both the lateral and basolateral amygdala nuclei and mice heterozygous for 
Neurod2 have reduced number of neurons in the amygdala (Lin et al., 2005). 
Behavioural analysis of Neurod2 heterozygous mice in fear learning tests revealed 
severe defects in emotional learning by alterations in key molecular regulations of 
emotional learning including the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) and γ-Aminobutyric acid (GABA) receptors as a result of Neurod2 
absence (Lin et al., 2005). Hence the dosage of Neurod2 is critical in regulation of 
genes involved in amygdala fear processing and emotional behaviour (Lin et al., 
2005). 
 
1.8.3 Neurod4 
Neurod4 also known as MATH-3 was initially cloned as Beta3 by Peyton et al., (1996) 
using partial degenerate primers binding other class II bHLH genes and the hamster 
insulin tumour cDNA library. Human Neurod4 was also independently cloned by 
Horikawa et al., (2000) by RT-PCR of adult human pancreatic islet mRNA. The 
Neurod4 gene maps to chromosomal location 12q13.2 in humans (Horikawa et al., 
2000) and chromosome 10 in the mouse (Tsuda et al., 1998). Neurod4 expression 
was detected robustly in the chicken dorsal root ganglia, spinal cord, retina, 
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diencephalon and metencephalon however Neurod4 transcripts were absent from 
the telencephalon/ cortex and a layer lining the ventricular zone (VZ) (Roztocil et el., 
1997). Since, class II bHLH proteins are not usually expressed in the VZ, Neurod4- 
expressing cells however are located at the interface between the proliferative and 
non-proliferative zones of the VZ where they have just left the cell cycle and have 
begun differentiating yet have not begun the migration process. Hence, Neurod4 was 
characterised to define the early and transient stage when a cell begins the 
differentiation process (Roztocil et al., 1997).  
 
1.8.4 Neurod6 
Neurod6 alternatively known as Nex1, MATH2 and ATOH2, belongs to the NeuroD 
subfamily of bHLH transcription factors (Guo et al., 2002) and has structural 
homology to the product of the Drosophila proneural gene atonal. Neurod6 was 
independently cloned in rat by Shimizu et al., (1995) and Bartholoma and Nave 
(1994) using degenerate primer and RT-PCR from rat cDNA. The Neurod6 gene of 
chromosomal location 7p15-p14 consists the two non-coding exons 1a and 1b, the 
single coding exon 2 and two intronic regions (Uittenbogaard et al., 2007). Neurod6 
is transcriptionally regulated via two promoter regions P1 and P2 that are under the 
control of CRE and C/EBP regulatory elements respectively (Uittenbogaard et al., 
2007). The NeuroD6 protein has a molecular size of 38.6 kDa and is 337 amino acids 
in length (Shimizu et al., 1995), with a glutametergic-rich N-terminal domain, 2 
transactivation domains (TAD1 and TAD2), surrounding the nuclear localization (NL) 
and the bHLH domains (Uittenbogaard et al., 2007). The human Neurod6 gene was 
also cloned from a human foetal brain cDNA library (Guo et al., 2002) which is highly 
homologous to mouse Neurod6 with a 98% protein sequence similarity differing in 
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only four amino acids. Furthermore, both the human and mouse bHLH domains have 
100% sequence similarity (Guo et al., 2002).  
 
1.8.4.1 Neurod6 expression in the brain 
Whole- mount in situ hybridisation on mouse embryos detected Neurod6 expression 
in the CNS from E11.5 in brain vesicles and the spinal cord (Shimizu et al., 1995). 
Later between E15.5 and E18.5, Neurod6 expression was detected more 
prominently in the cortical plate and mantle layer throughout the developing CNS 
however it is not ever expressed in the ventricular zone where progenitor cells are 
dividing. Therefore, Neurod6 expression is restricted to post-mitotic differentiating 
committed neurons. In the adult, Neurod6 expression is maintained in a number of 
regions throughout the brain detected in cortex, olfactory bulb, dentate gyrus, 
hippocampus and the cerebellum (Shimizu et al., 1995; Schwab et al., 1998; Schwab 
et al., 2000). Particularly, high levels of Neurod6 RNA are detected in the cortex 
however in other neural tissue regions the RNA levels are relatively lower. 
Furthermore, Neurod6 expression is specific to the nervous system since it is not 
detected in non-neural tissues (Shimizu et al., 1995).   
 
Since Neurod6 is expressed in several brain regions, changes in Neurod6 levels 
have been implicated in a number of clinical disorders including schizophrenia 
(Perez-Santiago et al., 2012), attention-deficit/ hyperactivity disorder (Ribases et al., 
2009), obsessive compulsive disorder (Mattheisen et al., 2015), heteropia (Castro et 
al., 2002), epilepsy (Dixit et al., 2016; Elliott et al., 2001) and alzheimer’s disease 
(Barral et al., 2015; Fowler et al., 2015; Li et al., 2015; Satoh et al., 2014).  
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In the mesencephalon, Neurod6 expression is detected at E11.5 (Lee, 1997) 
however the precise regions within the mesencephalon or in which neurons was not 
precisely documented in previous literature. In the microarray based gene profiling 
study by Chung et al., (2005) mentioned previously, a 5-fold enrichment of Neurod6 
expression was found in VTA-specific mDA neurons of the ventral midbrain 
compared to the SNc. However, the temporal and spatial distribution of Neurod6 in 
mDA neurons of the VTA has not been investigated. In this thesis, I will unravel the 
temporal and spatial expression patterns of Neurod6 specifically in mDA neurons.  
 
1.8.4.2 Role of Neurod6 in neurons 
 
1.8.4.2.1 Cell Fate & Subtype Identity 
 
In the CNS, another model of cellular diversity giving rise to functionally distinct cell 
types is the vertebrate retina. Retinal cells belong to a neuronal cell class that 
includes distinct cell types that have similar molecular, morphological and 
physiological neuronal properties that underlie shared function (Masland, 2004; 
Cherry et al., 2011). Neurod6 also has key roles specifically in regulating cell fate 
and defining subtype identity of retinal cells (Cherry et al., 2011; Kay et al., 2011). In 
the adult retina, Neurod6 is normally expressed by a subset of non-GABAergic, non-
glycinergic amacrine cells. Misexpression of Neurod6 by electroporation at P0 
induces amacrine cell fate more strongly and this alters neurite targeting of some of 
these amacrine cells (Kay et al., 2011; Cherry et al., 2011).  
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1.8.4.2.2 Axonal Outgrowth & Synaptic Plasticity 
 
In the CNS, apart from cell developmental processes such as neuronal differentiation, 
transcription factors belonging to the bHLH family have also been implicated in late-
stage functions including neurite outgrowth, target selection and synaptogenesis. 
Neurod6 functions to promote axonal outgrowth and synaptic plasticity via the 
regulation of downstream genes involved in synaptic remodelling and neurite 
extension. These include the growth associated protein 43 (GAP-43; Uittenbogaard 
et al., 2003) and the plasticity related gene 1 (Prg1; Yamada et al., 2008) are both 
direct targets of Neurod6. Neurod6 is capable of mediating neurite outgrowth in the 
absence of nerve growth factor by activating GAP-43 (Uittenbogaard et al., 2003).  
 
1.8.4.2.3 Differentiation & Neuronal Survival 
 
Neurod6 has key functions the maintenance of the differentiated state of neurons 
and in neuronal survival (Uitenbogaard and Chiaramello, 2005; Uitenbogaard et al., 
2010a). The precise mechanism by which Neurod6 promotes neuronal survival, 
similar to nerve growth factor (NGF), includes both the maintenance of expression 
of G1 phase cyclin-dependent kinase inhibitors and activation of key anti-apoptotic 
regulators (Uittenbogaard and Chiaramello, 2005). Key components of the Neurod6-
mediated transcriptional network that regulates neuronal survival are the p27kip1, 
p21WAP/cip1 and p16INK4a CDK inhibitor proteins belonging to the CIP/KIP and INK4 
families (Uittenbogaard and Chiaramello, 2005). 
Neurod6 also has a neuroprotective role in tolerance to mitochondrial oxidative 
stress by enhancing biogenesis (Baxter et al., 2012; Uittenbogaard et al., 2010b) and 
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in cytoskeletal organization (Kathleen Baxter et al., 2009). This highlights its cellular 
functions that may be important for the regulation of basic neuronal machinery and 
properties. Ultimately, Neurod6 is widely expressed throughout the CNS and has 
important functions in neuronal survival in cooperation with other members of the 
NeuroD family (Schwab et al., 2000; Bormuth et al., 2013). However, the precise 
expression patterns and role of Neurod6 in the midbrain dopamine region has not 
been investigated. This presents a gap in our knowledge of the unknown expression 
profiles and roles for NeuroD family of bHLH transcription factors in mDA neurons, 
which are a highly heterogeneous and diverse population of neurons, in the 
developing and adult brain. This thesis will address this gap in knowledge and 
provide further insights into the molecular heterogeneity of mDA neurons in relation 
to their axon target sites in the forebrain as well as the important roles for Neurod6 
and Neurod1 in promoting their survival.  
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1.9 Research Questions & Aims of this Thesis 
(i) Identification and molecular characterisation a novel mDA subset 
marked by the expression of Neurod6. This will be the main focus of 
Chapter 3.  
 
Objectives of this chapter will be firstly to characterise the temporal and spatial 
expression pattern of Neurod6 within the midbrain, documenting this for the first 
time. Secondly, to assess this mDA subset in relation to known and established 
molecular markers of mDA subpopulations and to other yet understudied less well 
documented molecular markers.  
 
(ii) To determine the role of Neurod6 in mDA neurons. This will be 
addressed in Chapter 4. 
  
Using a loss-of-function approach in Neurod6 mutants, the objectives will be to 
characterise any cellular mDA phenotypes in the VTA that may provide evidence 
for the function of Neurod6 in mDA neurons.  
 
(iii) To identify the mDA projection target site(s) within the forebrain of this 
Neurod6-marked mDA neuronal subset. This will also be addressed in 
Chapter 4.  
 
The objective here will be to firstly characterise any mDA axonal phenotypes in 
relevant forebrain regions of Neurod6 mutants. Secondly, to demonstrate 
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projections to specific forebrain targets of Neurod6-marked mDA neurons using 
fluorogold retrograde tracing methods.  
 
(iv) To determine roles for additional members of the NeuroD family of 
proteins in a Neurod6+ mDA subset. This will be presented in Chapter 5.  
 
Objectives of this chapter will be to firstly, elucidate expression of other NeuroD 
family members since these have been shown to have overlapping expression 
profiles in the brain. Secondly, since NeuroD members exhibit redundant roles in 
the hippocampus and cortex, generation of double mutants and assessing any 
cellular changes as a result of loss of more than one factor will be addressed.  
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Chapter 2. Materials & Methods 
 
2.1 Generation and genotyping of mutant embryos and 
animals 
We first generated Neurod6Cre/+;R26RYFP/YFP mice (referred to henceforth as Neurod6 
control mice) by sequential breedings of Neurod6Cre/+ animals (Goebbels et al., 2006) 
with R26RYFP/YFP reporter mice. We intercrossed control Neurod6Cre/+;R26RYFP/YFP 
mice to generate Neurod6Cre/Cre;R26RYFP/YFP single homozygous mutant embryos 
and mice. For double mutant studies, Neurod1LacZ/+;Neurod6Cre/+;R26RYFP/YFP mice 
were generated by breeding Neurod1LacZ/+ mice (Miyata et al., 1999) with 
Neurod6Cre/Cre;R26RYFP/YFP animals. These animals were then intercrossed to 
generate double homozygous mutant embryos and mice carrying different numbers 
of Neurod1 and Neurod6 mutant alleles. Neurod6 heterozygous and homozygous 
allelic deletions were determined by PCR genotyping for the Cre transgene and 
Neurod6-wild-type (WT) primer sequences. Neurod1 heterozygous and homozygous 
allelic deletions were determined by detection of the LacZ transgene and Neurod1-
WT primer sequences. Table 2-1 shows the primer sequences used for genotyping 
of these animals. All animals used were from mixed background. At all times, animals 
were handled according to the Society of Neuroscience policy on the use of animals 
in Neuroscience research, as well as the European Communities Council Directive. 
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Table 2-1 List of primer sequences for genotyping 
 
2.2 Tissue Preparation and Sectioning 
For in situ hybridisation and immunohistochemistry experiments, 2 months old adult 
animals were deeply anesthetised with ketamine-xylazine (10mg/mL and 1mg/ML, 
respectively) and were transcardially perfused with 100mM phosphate buffered 
saline (PBS, PH 7.4) followed by 4% (wt/vol) formaldehyde in PBS, pH 7.4. 
Embryonic, postnatal and adult brains were removed, immersion-fixed in fixative 4% 
(wt/vol) formaldehyde in 100mM phosphate buffer, pH 7.4 overnight at 4°C and 
subsequently cryoprotected in 30% (wt/vol) sucrose-PBS. Tissue samples were 
embedded in optimum cutting temperature (OCT) compound (VWR International, 
Poole, UK), and sectioned on a cryostat (CM3050S; Leica, Nussloch, Germany) as 
20 µm sections on Superfrost Plus microscope slides (25 x 75 x 1,0 mm; Thermo 
PCR  Forward primer sequence  Reverse primer sequence 
Neurod6-
WT 
 5’-
GAGTCCTGGAATCAGT
CTTTTTC-3’ 
 
 
5’-AGAATGTGGAGTAGGGTGAC-3’ 
 
Neurod6-
Cre 
 CRE A 
CCGCATAACCAGTGAA
ACAG 
 
 
Goebbels et al., 2006 
Rosa26R-
WT 
 5’-
GCACTTGCTCTCCCAAA
GTC-3’ 
 
 
5’-CTTTAAGCCTGCCCA GAAGA-3’ 
 
YFP 
 5’-
GGGCGTACTTGGCATA
TGAT-3’ 
 
 
5’-GCGAAGAGTTTGTCC TCAACC-3’ 
 
Neurod1-
WT 
 
Miyata et al., 1999 
 
Miyata et al., 1999 
LacZ     
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Scientific) for embryonic brains and 35 – 50 µm free-floating sections for postnatal 
and adult brains. 
 
For RNAscope experiments, adult animals were deeply anesthetised with ketamine-
xylazine (10mg/mL and 1mg/ML, respectively) and were transcardially perfused with 
10% neutral buffered formalin (NBF; Sigma-Aldrich). Brains were then removed and 
immersion-fixed in 10% NBF overnight at room temperature and then transferred into 
70% ethanol for storage. Brains were subsequently embedded in paraffin wax and 
processed into 4 µm sections collected onto Superfrost Plus microscope slides (25 
x 75 x 1,0 mm; Thermo Scientific) using the Leica RM2255 microtome.  
 
2.3 In Situ Hybridisation 
Section in situ hybridisations were performed as previously described (Vernay et al., 
2005) or using the RNAscope® 2.0 HD Brown Chromogenic Reagent Kit according 
to the manufacturer’s instructions (Advanced Cell Diagnostics, Hayward, CA). The 
following mouse antisense RNA probes have been used: Neurod6 (Brohl et al., 2008), 
Neurod1 (Lee et al., 1995), TH (Grima et al., 1985) and Grp (Wada et al., 1990). For 
RNAscope experiments, target probes for Neurod6 and Grp were designed by 
Advanced Cell Diagnostics. For each probe, a minimum of three control and three 
mutant brains were analysed at embryonic and adult stages.  
 
On day 1, sections were thawed at room temperature for 30 minutes. Slides were 
then washed three times in 1X diethylpyrocarbonate (DEPC)-treated PBS for 5 
minutes. Slides were then transferred into 200ml of acetylation solution (2.66ml 
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Trietahnolamine (TEA), 0.32ml concentrated hydrochloric acid (HCl), 0.5ml acetic 
anhydride) for 10 minutes shaking at room temperature (RT). Slides were washed 
again in 1X DEPC-treated PBS for 5 minutes each, 3 times. Slides were then 
transferred into a humidified chamber containing Whattman filter paper soaked with 
50% formamide, 5X SSC solution. Sections were then incubated in hybridisation 
buffer for 2 hours at RT making sure sections do not dry. Relevant probes were 
diluted in hybridisation buffer at 0.1g/ml (1:200 dilution, with a total of 200µl per slide). 
Once diluted, probes were denatured for 10 minutes at 95°C, vortexed and placed 
on ice for 5 minutes. Slides were covered with 200µl of diluted probes per slide and 
covered with glass coverslips to ensure even coverage of sections with probe. Slides 
were subsequently placed in a humidified chamber (containing filter paper soaked 
with 50% formamide, 5X SSC solution) overnight at 70°C in a water bath.   
 
On day 2, slides were washed in 5X SSC solution at RT for 5 minutes until coverslips 
had fallen away from slides revealing sections. Sections were subsequently washed 
in 0.2X SSC twice for 30 minutes each at 70°C temperature in a water bath. After 
this, sections were washed again in 0.2X SSC solution for another 5 minutes this 
time at room temperature on the shaker. Slides were then transferred into Buffer 1 
(0.1M Tris-HCl pH 7.5, 0.15M NaCl) solution for 5 minutes at room temperature. 
Sections on each slide were then covered in 1ml of blocking solution per slide for 2 
hours at room temperature. Anti-digoxygenin antibody mix was made up to a 1:1500 
dilution in buffer 1; 10% heat inactivated goat serum. After blocking, sections were 
incubated with 200µl of anti-digoxygenin antibody mix per slide, covered with 
parafilm and placed in a humidified chamber overnight at 4°C.  
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On day 3 of the in situ hybridisation experiments, parafilm was removed and slides 
were washed in buffer 1 solution 3 times, 5 minutes each at room temperature. Slides 
were rinsed in 1X NTMT twice for 10 minutes at room temperature. Staining solution 
made up fresh (3.5µl NBT, 3.5µl BCIP in 1X NTMT, 5% PVA solution per ml). 1ml of 
staining solution was placed evenly on each slide within a humidified chamber. Once 
covered in staining solution, slides were covered and left in humidified chamber in 
the dark at 37°C. Probe intensity signals were left to develop, ranging from few hours 
to day(s) depending on probe. If continuing staining the next day, sections were 
washed in 1X NTMT for 3 times for 10 minutes at room temperature and kept in the 
at 4°C overnight. If staining was completed, sections were washed first in 1X PBS to 
stop any further staining and the 3 times in water. Sections were left to dry and 
mounted with aquatex if not counter-stained with TH immunostaining. However, 
sections that required further immunostaining with TH antibody, were not dried but 
washed thoroughly in 1XPBS and incubated in appropriate primary antibody (see 
immunohistochemistry).  
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Table 2-2 Solutions used for In Situ Hybridisation experiments and their volumes 
made per batch experiment 
ml, millilitres; L, litre, SSC, saline- sodium citrate buffer; DEPC, diethylpyrocarbonate; 
mg, milligrams; pH, HCl, hydrochloric acid; NGS, normal goat serum; NaCl, sodium 
chloride; PVA, g, grams; RT, room temperature.  
 
 
Solution (total volume) 
 Reagents used to make 
solution (ml) 
 Storage 
temperature 
Pre-hybridisation buffer (50ml)  25ml deionised formamide 
12.5ml 20X SSC (DEPC) 
1.25ml tRNA (10mg/ml) 
2.5ml 100X Denhardt’s 
2.5ml 10mg/ml herring sperm 
6.25ml DEPC H2O 
 
 -20°C 
Buffer 1 (1L)  100ml 1M Tris-HCl pH 7.5 
37.5ml 4M NaCl 
Distilled H2O to 1L 
 RT 
 
5X SSC (1L) 
  
250ml 20X SSC 
750ml H2O Milli-Q® 
 RT 
 
0.2X SSC (1L) 
  
10ml 20X SSC 
990ml H2O Milli-Q® 
 RT / 70°C 
during 
incubation 
 
Blocking solution (100ml) 
  
10% NGS in 100ml Buffer 1 
solution 
 4°C 
 
NTMT 2X (500ml) 
  
25ml 4M NaCl 
100ml 1M Tris HCl pH 9.5 
50ml 1M MgCl2 
10ml 10% Tween-20 
315ml H2O Milli-Q® 
 RT/ 4°C if 
keeping 
slides 
overnight in 
this solution 
 
50% formamide, 5X SSC 
(200ml) 
  
100ml formamide 
50ml 20X SSC 
50ml H2O Milli-Q® 
 RT 
 
10% PVA (200ml) 
  
20g PVA powder 
200ml H2O Milli-Q® 
 RT 
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2.4 Immunohistochemistry 
For immunohistochemistry, 20 µm frozen cryosections were thawed at RT for 30 
minutes. Frozen cryosections or free-floating sections were washed 3 x 5minutes in 
1X PBS and subsequently incubated in 1% (wt/vol) bovine serum albumin (BSA) in 
100mM PBS blocking solution for 1 hour at RT. Sections were then incubated 
overnight at 4°C with the appropriate primary antibodies diluted in 1% BSA in 100mM 
PBS. On the second day, sections were washed thoroughly with 1X PBS and 
subsequently incubated for 1 hour at RT with appropriate secondary antibodies 
conjugated with a fluorochrome (Molecular Probes) diluted in 1% BSA in 100mM 
PBS. For nuclear staining, sections were incubated with 4',6- Diamidino-2-
Phenylindole, Dihydrochloride (DAPI; 1:10,000). Sections were then washed 
extensively overnight in 100mM PBS and mounted in Vectashield H-1000 (Vector 
Laboratories,Burlingame, CA). 
 
The following primary antibodies were used: sheep anti-GFP (1:1000; Bio-RAD/ AbD 
Serotec), rabbit anti-GFP (1:1000; Invitrogen), rabbit anti-TH (1:1000; Pelfreez), 
mouse anti-TH (1:500; Immunostar), sheep anti-TH (1:1000; Millipore); rabbit anti-
OTX2 (1:500, Baas et al., 2000); goat anti-OTX2 (1:500, R&D Systems); mouse anti-
CALBINDIN1 (1:1000, Swant); rabbit anti-ALDH1A1 (1:200, Abcam); rabbit anti-
NOLZ1 (1:200, Biorbyt); mouse anti-NEUROD1 (1:500, Abcam); rabbit anti-
NEUROD2 (1:1000, Abcam) and rabbit anti-TOM20 (1:1000; Santa Cruz 
Biotechnology).  
 
The following secondary antibodies were used: Alexa Fluor 594 donkey anti-rabbit 
(1:300; Molecular Probes), Alexa Fluor 488 donkey anti-sheep (1:200; Molecular 
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Probes), FITC donkey anti-sheep (1:200; Jackson ImmunoResearch Laboratories, 
Inc.), Alexa Fluor 647 donkey anti-mouse (1:200; Molecular Probes), Cy5 donkey 
anti-mouse (1:200; Jackson ImmunoResearch Laboratories, Inc.), Cy5 donkey anti-
sheep (1:200; Jackson ImmunoResearch Laboratories, Inc.).  
 
2.5 Cell Counting & Imaging 
For each brain, 50uM free-floating coronal cryosections were collected from the 
caudal to the rostral midbrain for immunohistochemistry with TH and GFP primary 
antibodies. Free-floating sections were subsequently mounted onto slides from 
caudal to the rostral midbrain and imaged using the Olympus Virtual Slide 
Microscope VS120-L100-W and ZEISS Apotome.2 Optical sectioning using 
structured illumination imaging systems. YFP+/TH+ double-positive cells were 
counted for one hemisphere of all midbrain sections to determine both the (i) total 
cell number and (ii) spatial distribution in controls and mutants at E18.5, P3, P7, P14 
and adult stage. For each stage, three control and three mutant brains were analysed. 
Image J and Fiji (National Institutes of Health, NIH) software was used for cell 
quantification. 
 
2.6 Statistical Analysis 
Statistical analysis was performed only on cell counts of sections from the central 
mDA region. All sections through the central mDA region (bregma from -3.28 to -3.80 
mm) contained 3 VTA nuclei, the PN, PBP and the posterior portion of the IF, SNc 
as well as two adjacent nuclei, the interpeduncular nucleus (IPN) and the red nucleus 
(RMC) (see schematic in Fig. 4-1I). Sections were matched according to the 
Chapter 2. Methods 
 
 79 
presence of these landmarks from the caudal to the rostral extent. Besides these 
anatomical features, the most rostral section of the central mDA region also has the 
emergence of the fasciculus retroflexus. For cell count comparisons between two 
groups, statistical significance was assessed using the unpaired Student’s t tests to 
determine differences in both the distribution and total number of TH+/YFP+ cells of 
the VTA in Neurod6 controls and Neurod6 mutants. When comparing cell number 
differences between more than two groups (Neurod6 control, Neurod6 mutant and 
Neurod1;Neurod6 double mutants), statistical significance was assessed by One-
way ANOVA (GraphPad Prism) with Tukey’s post-test comparing the means of each 
group to the mean of every other group.  
 
2.7 Assay for cell apoptosis  
To detect cell apoptosis, terminal deoxynucleotidyl transferase-mediated biotinylated 
UTP nick-end labelling (TUNEL) assays were performed using the TACS® 2 TdT 
DAB In Situ Apoptosis Detection Kit (Trevigen, R&D Systems; 4810-30-K). 10µM 
cryostat sections were immerse hydrated, fixed and immobilised in 1X PBS for 10 
minutes, then covered with 50-200µl of CytoninTM for 30 minutes. Samples were then 
washed twice in deionized water for 2 minutes each, then immersed in Quenching 
Solution (Methanol; 30% hydrogen peroxide) for 5 minutes. Samples were washed 
in 1X PBS for 1 minute, then immersed in 1X TdT Labelling Buffer for 5 minutes. 
Samples were covered with 50-200µl of Labeling Reaction Mix (TdT dNTP Mix; TdT 
Enzyme; 50X Cation Stock; 1X TdT Labeling Buffer) and incubated for 60 minutes 
at 37°C in a humidified chamber. Samples were then immersed in 1X TdT Stop 
Buffer for 5 minutes and washed twice in deionized water for 5 minutes each. 
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Samples were then covered with 50-100µl of Streptavidin-horse raddish peroxidase 
(Strep-HRP) solution and incubated for 10 minutes at 37°C in a humidified chamber 
to avoid evaporation. Samples were then washed twice in 1X PBS for 2 minutes each 
followed by immersion in DAB solution for up to 7-10 minutes. Samples were then 
washed twice again in deionized water for 2 minutes each. Once TUNEL was 
completed, sections were then analysed for TH expression by immunohistochemistry. 
 
2.8 Densitometry 
For the quantification of fluorescent intensity, images were acquired in structured 
illumination mode to achieve optical sectioning. Signal intensity of mitochondrial 
TOM-20 levels in YFP+/TH+ and YFP-/TH+ cells were quantified by Fiji image 
processing package. Regions of interest (ROIs) were accurately drawn around 
individual TH+ (YFP+ and YFP-) cells and readings of fluorescence intensity were 
only measured from the TOM-20 channel. Only mDA neurons showing the nucleus 
in the optic sections were included in the analysis (over 200 neurons were analysed 
per cell type per genotype, from at least 5 pictures per group), and background 
fluorescence values were subtracted from all the readings.   
 
2.9 Retrograde fluorogold axonal labeling 
The retrograde tracer Fluorogold (Millipore) was injected into the LS of 
Neurod6Cre/+;R26RYFP/YFP control and Neurod6Cre/Cre;R26RYFP/YFP mutant pups at 
postnatal day 10 (P10). Mice were anesthetized using isoflurane, and 1µl of 
Fluorogold (2% in 0.9% sodium chloride) and 2% BDA (Molecular Probes) was 
injected in both hemispheres. We adapted the stereotaxic coordinates of the atlas of 
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Developing Mouse Brain (Paxinos and Watson, 2007) and the glass microsyringe 
was placed in the brain with the tip at 0,3 mm anterior to Bregma, 0,2 mm lateral of 
the midline and 1,8 mm from the surface of the brain. Mice were sacrificed 3 days 
after injection for further analysis. Location of the injection sites were confirmed by 
staining the section with streptavidin- conjugated to Alexa Fluor 568 that binds to 
BDA.  
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Chapter 3. Neurod6 is a novel marker for a subset of 
VTA mDA neurons 
 
3.1 Introduction 
mDA neurons are mostly found in the SNc and VTA and regulate multiple brain 
functions, including voluntary movement, working memory, emotion and cognition 
(Bjorklund and Dunnett, 2007). These neurons project to the forebrain and were 
initially thought of as a homogenous group of neurons based on their common use 
of dopamine as a neurotransmitter for intercellular communication. However, it is 
now becoming clear that mDA neurons are heterogenous in regard to their target 
and afferent projections (Roeper, 2013; Beier et al., 2015; Menegas et al., 2015), 
firing patterns (Roeper, 2013) and gene expression profiles (Poulin et al., 2014), all 
of which impact on their functional properties. mDA neurons projecting to striatal 
spiny projection neurons in the nucleus accumbens medial shell use glutamate as a 
co-transmitter (Hnasko et al., 2010; Stuber et al., 2010), whereas those projecting to 
the dorsal striatum use GABA (Tritsch et al., 2012). Furthermore, intact-brain 
analyses using a combination of whole brain imaging, optogenetics, viral tracing and 
fiber photometry, has revealed that different subsets of SNc neurons contribute to 
different nigrostriatal circuits carrying different information streams (Lerner et al., 
2015). 
 
Despite the emerging evidence for functionally distinct subsets of mDA neurons, we 
still know little of the molecular underpinnings of this functional diversity. Within the 
two classical subpopulations, the A9-SNc and A10-VTA, further complexity and new 
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molecular subsets can now be uncovered. It is necessary that these be identified 
and characterised in order to shed light on the heterogeneity of mDA neurons, 
unravel the roles of genes in individual mDA subsets and to understand differential 
vulnerability of mDA neurons in disease and dysfunction. Specific studies have 
investigated the heterogeneity of mDA neurons suggesting that mDA neurons within 
each sub-population also contain heterogenous and mixed subsets. Recent 
transcriptome analyses of VTA and SNc mDA neurons have provided lists of genes 
differentially expressed between these two anatomically separable groups of 
neurons (Grimm et al., 2004; Chung et al., 2005). Microarray based gene profiling of 
the A9-SN and A10-VTA specific subpopulations was conducted by Chung et al., 
2005, revealing a number of differentially expressed genes between these two mDA 
subpopulations. mDA neurons specifically from the SNc and VTA were isolated by 
rapid TH-immunostaining followed by laser capture microdissection (LCM) of SNc 
and VTA neurons of adult mice. This was followed by microarray analsysis of 
differentially expressed genes and validation by RT-PCR. Their analysis revealed a 
number of transcription factors that are preferentially expressed in the VTA (Chung 
et al., 2005). These include orthodenticle homeobox 2 (Otx2; Di Salvio et al., 2010), 
Calbindin D28K (Liang et al., 1996) aldehyde dehydrogenase family 1 (Aldh1a1/ 
Raldh1; Chung et al., 2005; Jacobs et al., 2007). One of these differentially 
expressed genes is the basic helix-loop-helix transcription factor NEUROD6, 
alternatively known as NEX1, MATH2 and ATOH2. NEUROD6 belongs to the 
NEUROD subfamily of bHLH transcription factors. In the midbrain, there is 
preferential expression by nearly a 5-fold increase of Neurod6 within the VTA 
compared to the SNc according to the microarray analysis of mDA subpopulations 
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(Chung et al., 2005). However, the expression and role of NEUROD6 within the 
midbrain is unknown and not yet identified.  
 
Neuropeptides, lipoproteins, growth factors and G-protein coupled receptors were 
also seen to be upregulated in the VTA compared to the SNc according to the LCM-
microarray analysis conducted by Green et al., 2005 and Chung et al., 2005. These 
included gastrin releasing peptide (Grp), lipoprotein lipase (Lpl), insulin growth factor 
binding protein 4 (Igfbp4) and G-protein 83 (Gpr83; Chung et al., 2005). The 
expression patterns and roles of these molecules in VTA mDA neurons is still 
unknown.  
 
In this chapter, I elucidate the expression of Neurod6 within the VTA, document 
molecular characterisation of a Neurod6-marked mDA subset using gene expression 
analysis in Neurod6 control mice (Goebbels et al., 2006) according to known and 
unknown VTA markers.  
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3.2 Results 
 
3.2.1 Neurod6 is expressed in a subset of post-mitotic VTA mDA neurons 
 
I first examined the expression of Neurod6 in the mouse midbrain by RNA in situ 
hybridisation from embryonic days 12.5 (E12.5) onwards. Neurod6 expression was 
not detected at E12.5 (data not shown) but transcripts were found localised in the 
ventral regions of the VTA at E15.5 (Fig. 3-1A,A’) and E17.5 (3-1B,B’). To determine 
whether Neurod6 is expressed in mDA neurons, immunohistochemistry for TH 
protein expression was conducted following detection of Neurod6 transcripts. 
Neurod6 transcripts were co-localised with TH protein in the VTA at embryonic 
stages (brown staining in Fig. 3-1A,A’,B,B’) and its expression was maintained in a 
subset of ventral VTA TH+ neurons in adult mice (Fig. 3-1C-D’). In contrast, Neurod6 
was not detected in TH+ neurons of the SNc at any stage (Fig. 3-1C-D’ and data not 
shown). Altogether, these results demonstrate that Neurod6 is specifically expressed 
in a small subset of mDA neurons in the VTA from E15.5. to adulthood. 
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Figure 3-1 Selective expression of Neurod6 in mDA neurons in the VTA 
A-D, In situ hybridisation for Neurod6 combined with immunohistochemistry for TH 
showing that Neurod6 expression is restricted to TH+ mDA neurons located in 
ventral regions of the VTA from E15.5 to adult stage (A-C). In contrast, Neurod6 is 
not expressed in TH+ mDA neurons in the SNc (D). A’-D’, Higher magnification of 
boxed regions in corresponding panels A-D. Scale bars: (A) 200μm, (A’) 10μm.    
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3.2.2 YFP faithfully mimics endogenous Neurod6 expression in Neurod6 
control mice   
To facilitate co-localisation studies between Neurod6 and other genes expressed in 
mDA neurons in the VTA, and since a NEUROD6-specific antibody is not available, 
I used a mouse line where the coding region of Neurod6 has been replaced by the 
Cre recombinase gene (Goebbels et al., 2006). I permanently labelled the cells in 
which the Neurod6 promoter has been active by breeding these Neurod6Cre mice to 
R26RYFP reporter mice that conditionally express YFP in a Cre-dependent manner. I 
first confirmed that the CRE recombinase protein is co-expressed with YFP in VTA 
TH+ mDA neurons of Neurod6Cre/+;R26RYFP/YFP mice at P3 (Figure 3-2A) . I then 
showed that YFP expression is similar to endogenous Neurod6 expression in the 
VTA of heterozygous Neurod6Cre/+;R26RYFP/YFP adult mice by conducting multiplex in 
situ hybridisation using RNAscope® followed by GFP antibody labelling. Indeed, all 
YFP+ neurons expressed Neurod6 in the adult VTA (Figure 3-2B). Furthermore, 
since there is no working available antibody for NEUROD6, I used a pan-NeuroD 
antibody that detects all members of the NEUROD family of proteins, and found that 
all YFP+TH+ cells were pan-NEUROD+ in Neurod6Cre/+;R26RYFP/YFP adult control 
mice (Figure 3-2C). Altogether, these results establish that YFP expression in 
Neurod6Cre/+;R26RYFP/YFP mice faithfully reflects endogenous Neurod6 expression, 
and that expression of Neurod6 is maintained in neurons once it has been initiated. 
I therefore used YFP expression in these mice as a marker of Neurod6+ mDA 
neurons in subsequent experiments.  
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Figure 3-2 YFP+ cells express endogenous Neurod6 in Neurod6Cre/+;R26RYFP/YFP 
controls 
A, Triple antibody labelling showing that CRE is co-expressed with YFP in TH+ 
mDA neurons in the VTA of Neurod6Cre/+;R26RYFP/YFP pups at P3. B, In situ 
hybridization of Neurod6 combined with immunohistochemistry for YFP showing 
that all YFP+ cells express Neurod6 transcripts (brown dots shown by red arrows) 
in adult Neurod6Cre/+ mice (blue asterix* is dust). C, Triple antibody labelling using 
a pan-NEUROD antibody that recognizes all members of the NeuroD family of 
bHLH transcription factors with YFP in TH+ mDA neurons in the VTA of 
Neurod6Cre/+;R26RYFP/YFP adult mice shows that all YFP+ cells are pan-
NEUROD+. Scale bars: (A) 100μm, (B) 20μm. 
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3.2.3 Neurod6 identifies a subset of OTX2+, ALDH1A1+, CALBINDIN1+ mDA 
neurons in the VTA 
 
Earlier studies have shown that expression of the homeodomain-containing 
transcription factor OTX2 in the midbrain is restricted to mDA neurons in the VTA (Di 
Salvio et al., 2010b; Di Salvio et al., 2010a). Moreover, mDA neurons in the VTA can 
be further subdivided into dorsal, central and ventral layers based on co-expression 
of OTX2 with other markers including CALBINDIN1 and ALDH1A1 (Di Salvio et al., 
2010a). I therefore performed triple antibody labelling experiments for TH, YFP and 
these three proteins individually, to compare their expression patterns with that of 
Neurod6 in mDA neurons. The results show that all Neurod6+ cells express OTX2 
(Figure 3-3A), CALBINDIN1 (Figure 3-3B) and ALDH1A1 (Figure 3-3C) indicating 
the existence of a group of VTA neurons co-expressing all four genes.  
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Figure 3-3 Identification of a novel subset of mDA neurons in the VTA that 
expresses Neurod6, OTX2, CALBINDIN1, ALDH1A1 
A, B, C, Triple antibody labelling showing that all YFP+TH+ mDA neurons express 
OTX2 (A), CALBINDIN1 (B) and ALDH1A1 (C) in the VTA of adult 
Neurod6Cre/+;R26RYFP/YFP mice. Higher magnification of boxed regions in 
corresponding panels. Scale bars: 100μm and high magnification panels 20μm. 
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3.2.4 Neurod6+ mDA neurons also express the VTA markers NOLZ1 and Grp  
I also compared the expression of YFP and two other VTA-enriched genes, Nolz1 
(Panman et al., 2014) and Grp [GRP; Paul Allen Brain Atlas, (Chung et al., 2005)].  
Triple antibody labelling experiments for TH, YFP and NOLZ1 proteins revealed that 
YFP+TH+ mDA neurons co-express NOLZ1 in Neurod6Cre/+;R26RYFP/YFP adult 
controls (Figure 3-4A-D). NOLZ1 was also broadly expressed in other VTA neurons 
that were YFP-/TH+ (Figure 3-4A-D). Grp has been reported to be enriched in the 
VTA (Chung et al., 2005) however Grp mRNA cellular localisation in mDA neurons 
has not been observed. In situ hybridisation experiments for Grp followed by 
immunofluorescence antibody labelling of TH over the same sections, detected Grp 
mRNA transcripts in a subset of the ventral VTA of Neurod6Cre/+;R26RYFP/YFP controls 
(Figure 3-4E). These Grp transcripts were localised specifically in TH+ mDA neurons 
of the ventral VTA (Figure 3-4E). RNAscope experiments using a Grp probe followed 
by antibody staining for GFP in Neurod6Cre/+;R26RYFP/YFP adult mice revealed that 
Grp was expressed in all Neurod6+ mDA neurons as well as in some surrounding 
YFP- cells (Figure 2B). In summary, our expression studies have identified a novel 
subset of VTA mDA neurons that co-express Neurod6, OTX2, CALBINDIN1, 
ALDH1A1, NOLZ1 and Grp.  
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Figure 3-4 Neurod6+ mDA neurons of the VTA also co-express NOLZ1 and Grp 
A-D, Triple antibody labelling showing that all YFP+TH+ mDA neurons express 
NOLZ1 (A) in the VTA of adult Neurod6Cre/+;R26RYFP/YFP mice (A-D). (E) In situ 
hybridisation for Grp combined with immunohistochemistry for TH showing that Grp 
is expressed in TH+ mDA neurons located in ventral regions of the VTA in adult 
Neurod6Cre/+;R26RYFP/YFP mice (F) In situ hybridisation (RNAscope) of Grp 
combined with immunohistochemistry for YFP showing that Grp transcripts are 
detected in both YFP+ (red arrows) and YFP- (blue arrowheads) cells in the VTA of 
adult Neurod6Cre/+ mice. Scale bars: (A-E) 100μm, (F) 20μm.   
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3.3 Discussion 
 
This chapter reveals the identification of a novel subset of mDA neurons in the VTA 
that are marked by the expression of the bHLH transcription factor NEUROD6. 
Neurod6+ VTA neurons express a combination of molecular markers including OTX2, 
ALDH1A1, CALBINDIN1 and Grp and project specifically to the lateral septum region 
of the forebrain. 
 
Despite increasing evidence of heterogeneity among mDA neurons, there is still a 
paucity of specific markers to identify distinct mDA neuron subsets. mDA neurons in 
the VTA have been subdivided into molecularly distinct subsets based on 
combinational expression of more broadly expressed genes (Di Salvio et al., 2010a). 
For example, OTX2, CALBINDIN1 and ALDH1A1 mark a ventral subset of VTA 
neurons, while OTX2+/CALBINDIN1+ and OTX+/GIRK2+ label central and dorsal 
VTA neurons, respectively. Our molecular characterisation shows that the ventral 
VTA subset can be further subdivided by the expression of Neurod6. Recent studies 
using single-cell transcriptome profiling have also identified a molecularly distinct 
subset of mDA neurons in the VTA that co-expresses Otx2, Aldh1a1, Calb, Grp, Lpl 
and Adcyap1 (Poulin et al., 2014). Since Neurod6+ mDA neurons also express the 
first four of these markers, it is probable that Neurod6 marks the same subset. 
Neurod6 is however uniquely expressed in this neuronal subset, in contrast to OTX2, 
CALBINDIN1 and ALDH1A1, which all have a broader expression in mDA neurons 
(Di Salvio et al., 2010a; Poulin et al., 2014).  
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Molecular characterisation of Neurod6+ mDA neurons, including their 
expression of the neuropeptide Grp that is implicated in the regulation of memory 
associated with fear and emotional arousal, social interaction and food intake 
(reviewed in (Roesler and Schwartsmann, 2012), will aid in classifying these neurons 
and studying their potential functions in regulating memory and emotional behaviours.  
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Chapter 4. Neurod6 is required for the survival of 
mDA neurons projecting to the LSi 
 
4.1 Introduction 
NEUROD6 also specifies the fate of a subtype of retinal amacrine cells (Cherry et 
al., 2011; Kay et al., 2011) and it has been implicated in the survival of cultured rat 
pheochromocytoma PC12 cells, where it enhances mitochondrial biogenesis and 
regulates cytoskeletal organization (Uittenbogaard and Chiaramello, 2005; 
Uittenbogaard et al., 2010; Baxter et al., 2012). Neurod6-mediated neuronal survival 
of these cells involves an increase in mitochondrial DNA copy number and content 
as seen by an increase in mitochondrial transcription factor A (TFAM) levels (Baxter 
et al., 2012). In addition, Neurod6 enhances the bioenergetics reserve of these 
neurons by increasing the levels of specific respiratory subunits (Baxter et al., 2012). 
Neurod6 is also able to increase mitochondrial membrane potential as visualized by 
increased fluorescence intensity of the TMRM dye (Baxter et al., 2012). Furthermore, 
work on PC12 cells demonstrate that Neurod6 is neuroprotective by making these 
neurons more resistant to oxidative stressors such as rotenone (Baxter et al., 2012).   
These important roles of NEUROD6 in protection and neuronal survival raised the 
possibility of similar roles for this factor in mDA neurons.  
The A10-VTA mDA neurons project to several forebrain target regions. VTA mDA 
neurons projecting via the mesocortical pathway terminate their axons in the cortex; 
cingulate, prefrontal and perirhinal cortices. Other VTA mDA neurons project via the 
mesolimbic pathways to innervate various limbic structures including the amygdala, 
olfactory tubercle and the lateral septum. 
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A number of techniques have been used to identify axon target sites of mDA 
neurons in the VTA and SNc including both retrograde and anterograde tracing. 
Amongst the several conventional retrograde tracers that are available, fluorogold 
(FG; chemical name: hydroxystilbamidine) is particularly advantageous possessing 
several properties that make it suitable for retrograde tracing of mDA axons. FG is a 
fluorescent dye that emits different frequencies of light when bound to DNA and RNA. 
The beneficial properties of FG include that it has intense fluorescence and has high 
resistance to fading remaining in labelled neurons for long periods of time with a wide 
latitude of survival times ranging from 4 days to 2 months (Naumann et al., 2000). 
Additionally, it is detectable by conventional fluorescence microscopy using an 
ultraviolet excitation filter and can be photographed digitally. More importantly, FG 
can be injected into any PNS and CNS structure, it does not diffuse from labelled 
cells and is not taken up by intact undamaged fibers of passage although this was 
disputed in earlier studies it is now well established that only fibers terminating at the 
site of injection take up FG into their presynaptic terminals and retrogradely transport 
FG back to their cells of origin labelling their cell bodies with FG. Lastly, FG is 
compatible with all other histochemical techniques used in the study of the nervous 
system including immunohistochemistry making co-labelling experiments with other 
mDA molecular markers and retrograde-labelled mDA cells possible for the 
identification of targets sites of molecularly-defined subsets.  
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4.2 Results 
 
4.2.1 Neurod6 is required for the survival of a subset of VTA mDA neurons 
 
To determine the role of Neurod6 in mDA neurons, I analysed Neurod6Cre/Cre; 
R26RYFP/YFP homozygous mutant mice. The total number and spatial distribution of 
Neurod6+ mDA neurons along the rostral-caudal axis of the VTA were evaluated by 
immunohistochemistry for TH and YFP at E18.5, postnatal day 3 (P3), P14 and 2 
months (Figure 4-1A-H and data not shown). I focused the quantitative analysis on 
anatomically defined sections in the central mDA region (see Materials and Methods), 
which contain the highest numbers of Neurod6+ cells (approximately 50% of the total 
number of VTA Neurod6+ mDA neurons; Figure 4-1L-N) and displayed a loss of 
Neurod6+ mDA neurons. At E18.5, I did not observe a significant difference in the 
total numbers of YFP+/TH+ cell in the central mDA region between Neurod6 mutant 
and control embryos (Table 4-1). At postnatal stages in contrast, there was a 
significant reduction in numbers of TH+/YFP+ mDA neurons in this region of Neurod6 
mutant compared to control mice (28% of control numbers at P3, 31% at P14 and 
32% at 2 months; Figure 4-1 and Table 4-1). The VTA in adult mice can be further 
subdivided into several nuclei, including the IF, dorsal (dPN) and ventral paranigral 
nucleus (vPN), and PBP (Oades and Halliday, 1987) (Figure 4-1I). YFP+/TH+ cells 
were found in all these nuclei in Neurod6 control mice (Figure 4-1J) and were missing 
specifically in the IF, dPN and PBP in Neurod6 mutant mice (Figure 4-1K). 
Altogether, these results show that the deletion of Neurod6 results in a loss of 
approximately 30% Neurod6+, TH+ mDA neurons in the central mDA region between 
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E18.5 and P3 that persists at adult stages. YFP+/TH+ mDA neurons that subsist in 
the absence of Neurod6 are localised in the vPN and the PBP (Figure 4-1K). 
 
Figure 4-1 Partial reduction in the number of Neurod6+ mDA neurons in the 
absence of NEUROD6 function 
A-H, Immunohistochemistry for both YFP and TH on coronal sections from the 
caudal to the rostral extent of the mDA region at P14. Reduced numbers of 
YFP+,TH+ neurons are observed in the central mDA region (B,C,F,G), while there 
is no apparent change in the numbers of YFP+TH+ mDA neurons in the rostral and 
caudal midbrain at P14. I, Schematic diagram showing the positions of mDA nuclei 
in the VTA and anatomical landmarks. J,K, Double antibody labelling of YFP and 
TH  on a section through the central mDA region shows that YFP+TH+ neurons are 
lost mostly in the dorsal paranigral (PN), parabrachial (PBP) and interfascicular (IF) 
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nuclei (only the YFP channel is shown). L-N, Graph showing the number of 
YFP+,TH+ mDA  neurons analysed by immunohistochemistry on coronal midbrain 
sections from the caudal to the rostral extent of the mDA region at different stages. 
Neurdo6+ mDA neurons in the VTA are lost predominantly in the central mDA 
region corresponding to sections demarcated by red vertical lines.  RMC; red 
nucles; ml, medial lemiscus; SNc, substantia nigra pars compacta; VTA, ventral 
tegmental area.  Error bars denote SEM. * p<0.05; **p<0.01 (Student’s t test). 
Scale bars: (A-H) 200μm, (J,K) 100μm. 
 
 
 
Table 4-1 Loss of YFP+/TH+ cells in the central mDA region of 
Neurod6Cre/Cre;R26RYFP/YFP mutants per brain hemisphere 
This table shows the raw data of the numbers of mDA neurons counted per brain 
hemisphere in the central mDA region and the results from statistical analysis, 
comparing cell counts between Neurod6 mutant and control brains at each stage 
using the unpaired Student’s t test. n, number of brain samples analysed; S.E.M, 
standard error of the mean; n.s, not significant. 
 
 
 
Next, I asked whether the absence of Neurod6+ neurons in Neurod6 mutants 
from P3 onwards was due to apoptosis, and I defined the precise timing of elimination 
of these cells, by conducting TUNEL analysis between E18.5 and P3. Many cells in 
the VTA of Neurod6 mutant mice at P2 were TUNEL+ and expressed TH, while 
TUNEL+ cells were very rarely observed in control mice at this stage (Figure 4-2A), 
indicating that Neurod6+ VTA neurons die from apoptosis at early postnatal stages 
in the absence of Neurod6. 
 
  E18.5  P3  P14  Adult 
n  3  3  3  3 
Neurod6 Controls (Mean ± S.E.M)  200 ± 3  232 ± 5  207 ± 1  270 ± 16 
Neurod6 Mutants (Mean ± S.E.M)  211 ± 27  167 ± 10  143 ± 14  185 ± 26 
% of YFP+/TH+ mDA cells lost in 
mutants relative to controls  
 
N/A  28%  31%  32% 
Average number of cells lost in 
mutants (Mean ± S.E.M) 
 
N/A  65 ± 14  65 ± 14  85 ± 15 
significance   n.s  **  **  * 
p-value  0.69  0.004  0.001  0.05 
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The mechanisms of Neurod6-mediated neuronal survival have been 
extensively studied in PC12 cells where Neurod6 functions to protect against 
oxidative stress by sustaining mitochondrial mass (Uittenbogaard et al., 2010). To 
assess changes in mitochondrial mass prior to neuronal cell death in Neurod6 mutant 
VTA neurons, I examined the expression of the mitochondrial import receptor subunit 
(TOM-20) at E18.5. TOM-20 expression level in YFP+/TH+ VTA neurons, measured 
by densitometric analysis, was significantly decreased in Neurod6 mutant compared 
to control embryo (Figure 4-2B). A smaller but significant reduction in TOM-20 
labelling was also observed in YFP- (Neurod6-)/TH+ mDA neurons (Figure 4-2B). 
These results indicate a robust reduction in mitochondria mass in both Neurod6+ 
and Neurod6- mDA neurons, and the difference between these two neuronal 
populations is also significant. Therefore, the sustenance of a subset of VTA neurons 
by Neurod6 is likely to involve the maintenance of their mitochondrial mass. 
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Figure 4-2 Loss of NEUROD6 function results in cell death and reduced 
mitochondrial mass in mDA neurons 
A, Apoptotic cells (arrowheads) revealed by TUNEL analysis are observed in the 
TH+ mDA region of Neurod6 mutant, but not in control pups at P2. B, Reduction in 
mitochondria mass measured by the mean fluorescence (normalised to cell area) 
of neurons analysed by immunohistochemistry with Tom20, TH and YFP (AU, 
arbitrary units) in Neurod6 control and mutant embryos at E18.5. n, number of 
neurons analysed. ** p<0.01; ****p<0.0001 (one-way ANOVA, with Tukey’s post-
test). Scale bar 200μm. 
 
 
4.2.2 Specific changes in axon projections of mDA neurons to the lateral 
septum in adult Neurod6 mutant mice  
The loss of a subset of VTA neurons in Neurod6 mutant mice is likely to affect the 
connectivity between the VTA and other brain regions. To address this possibility, I 
first compared the axon projections of mDA neurons in adult Neurod6 mutant and 
control mice by immunohistochemistry for TH. I analysed the neuronal projection 
targets of VTA neurons (A10) in the septum, prefrontal cortex, nucleus accumbens, 
amygdala and olfactory tubercle. In control mice, a dense arborisation of TH+ axons 
was observed in the intermediate lateral septum (LSi) and fine varicosities of TH+ 
mDA axons were found in the dorsal lateral septum (LSd) (Figure 4-3A,B). The dense 
arbor in the LSi was completely absent in Neurod6 mutants, while the axons of the 
LSd were unaffected (Figure 4-3A,B). TH+ mDA axons in all other A10 neuronal 
target sites also appeared normal in Neurod6 mutant mice (Figure 4-3E-J). The loss 
of both Neurod6+ neurons and TH+ axonal projections in Neurod6 mutant mice 
suggests that Neurod6+ VTA neurons project to the lateral septum. 
The specific loss of TH+ mDA axons in the LSi was also observed at P3, P7 
and P14 (data not shown). I examined the septal target site at E18.5 before the loss 
of YFP+ mDA neurons in mutant embryos, however TH+ fibres were not detected in 
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the dorsal lateral septal areas of control embryos, suggesting that at this stage TH+ 
mDA axons have not yet reached this target site (Figure 4-3C,D).  
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Figure 4-3 TH+ mDA axon projections to the intermediate region of the lateral 
septum are specifically missing in adult Neurod6 mutant mice 
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A,B, TH immunohistochemistry show specific loss of axon projections to the 
intermediate region (Lsi) but not to the dorsal region (LSd) of the lateral septum in 
Neurod6 mutant adult mice. C,D, TH+ axon projections from mDA neurons have 
reached the ventral region of the lateral septum (LS), but no TH+ fibres were found 
dorsally in the lateral septum of Neurod6  mutant embryos at E18.5. E-J, TH+ mDA 
neuronal projections to other target sites of the VTA including nucleus accumbens 
(NAc), olfactory tubercle (OT), amygdala (Amg) and prefrontal cortex (PFC) appear 
normal in Neurod6 mutant compared to control adult mice. TH+ axons of SNc mDA 
neuronal projections to the striatum (Str) were also unaffected. MS, medial septum; 
LSv, lateral septum, ventral; MS, medial septum; cc, corpus callosum; ac, anterior 
commissure. Insets in G-J show higher magnification of boxed region. Scale bar 
200μm. 
 
 
4.2.3 Fluorogold retrograde labelling demonstrates that Neurod6+ mDA 
neurons project to the lateral septum 
 
Next, to determine whether the lateral septum is a specific target site for Neurod6+ 
mDA neurons, collaborators performed fluorogold (FG) retrograde labelling 
experiments. FG was injected into the lateral septum of Neurod6 control and mutant 
pups at P10 and retrograde transport of FG into cell bodies of mDA neurons was 
analysed at P13 (Figure 4-4A). I first confirmed that FG had been specifically injected 
into the LSd and LSi regions of the septum by staining for BDA, which was co-
injected with FG. Coronal sections of the forebrain at the level of the septum showed 
BDA+ fibres in the lateral septal region, but not in the adjacent striatal region (Figure 
4-4B). In the midbrain of Neurod6+ control mice at P13, FG labelled most YFP+/TH+ 
mDA neurons in the IF, dPN, vPN and PBP of the VTA, demonstrating that Neurod6+ 
mDA neurons are lateral septal-projecting neurons (Figure 4-4C). In Neurod6 mutant 
mice, intra-septal FG injections retrogradely labelled many of the YFP+/TH+ mDA 
neurons that remain in the vPN and PBP of the VTA, indicating that these neurons 
project to the LSd and their axons likely correspond to the remaining TH+ fibres in 
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the LSd of Neurod6 mutants (Figure 4-4D). Altogether, these results suggest that the 
YFP+/TH+ mDA neurons missing in Neurod6 mutant animals project to the LSi, while 
the remaining YFP+/TH+ cells in these mutants project to the LSd. 
 
Figure 4-4 Fluorogold retrograde labelling experiments show that Neurod6+ mDA 
neurons project to the dorsolateral and intermediate region of the lateral septum 
A, Schematic diagram indicating the position of fluorogold injection in the injected 
brain and the schedule of the experiment. B, Biotin-dextran is detected specifically 
in the intermediate region (LSi) as well as the dorsal region (LSd) of the lateral 
septum but not in the adjacent striatal regions. C, D. Injection of fluorogold into the 
septal region results in its retrograde transport of fluorogold into YFP+ TH+ mDA 
cell bodies in Neurod6 control (C) and mutant (D) mice at P18. Scale bars: (B) 
100μm, (C,D) 200μm, high magnification panels 20μm.    
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4.3 Discussion 
 
In the previous chapter, I reported the identification of a novel subset of VTA neurons 
marked by the expression of Neurod6 and the molecular characterisation of this 
subset. In this chapter, I have examined the role of Neurod6 in the survival of mDA 
neurons by analysing Neurod6 mutants as well as controls. My analysis revealed a 
30% reduction in the number of Neurod6+ mDA neurons in the VTA of Neurod6 
single mutant mice at P3, and this phenotype was maintained in adult mutant mice. 
Loss of these neurons was accompanied by loss of TH+ fibres in the LSi of Neurod6 
single mutants, indicating that Neurod6 alone is required for the survival of LSi-
projecting mDA neurons.  
 
My anatomical studies have demonstrated that Neurod6+ mDA neurons are 
distributed in the PBP, PN and IF nuclei of the adult VTA. These neurons are found 
in similar numbers and with comparable spatial distributions along the rostral-caudal 
and medial-lateral axis of the midbrain from E18.5 to adult stage, suggesting that 
Neurod6 expression is established in mDA neurons during embryogenesis and 
persists through adulthood (Table 4-1). My findings therefore provide evidence for a 
developmental heterogeneity of mDA neurons that likely has implications for their 
adult function and for homeostasis.  
 
NEUROD6 has been shown to have a neuroprotective role in PC12 cells serum 
deprived or treated with the mitochondrial stressor rotenone, and to act by enhancing 
mitochondrial biogenesis (Uittenbogaard et al., 2010; Baxter et al., 2012). Consistent 
with these findings, I observed a decrease in mitochondria mass before the death of 
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Neurod6 mutant mDA neurons, suggesting that defects in energy metabolism 
contribute to the apoptosis of these neurons. Alternatively, changes in mitochondria 
mass might be an indirect consequence of neurons undergoing apoptosis because 
of the absence of anti-apoptotic factor regulated by NEUROD6.  Support for the latter 
mechanism comes from the finding that mitochondria mass was decreased in both 
YFP-negative (Neurod6-negative) as well as YFP+ mDA neurons (Figure 4-2B) and 
from the report that Neurod6 regulates the expression of anti-apoptotic factors in 
PC12 cells (Uittenbogaard and Chiaramello, 2005). 
 
Fluorogold retrograde tracing experiments established that Neurod6+ neurons 
project to the lateral septum. In this region, Neurod6+ mDA neurons project to both 
the LSi and LSd. Other VTA neurons also project to the lateral septum, since some 
of the mDA neurons labelled by fluorogold did not express Neurod6. Consistent with 
earlier studies in the rat, TH+ axon projections to the septum become established at 
early postnatal stages since the TH+ fibres were observed in P3 pups and not in 
E18.5 embryos (Antonopoulos et al., 1997). The role of dopamine in the lateral 
septum is poorly studied. Lesions of septal dopaminergic terminals by injection 6-
hydroxydopamine into the lateral septum of rats result in deficits in spatial memory 
tasks (Simon et al., 1986). 
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Chapter 5. Neurod6 and Neurod1 regulate the 
survival of LS-projecting mDA neurons 
 
5.1 Introduction 
NEUROD6 belongs to the NEUROD subfamily of bHLH transcription factors, which 
consists of 4 members including NEUROD1, NEUROD2, NEUROD4 and NEUROD6 
(Bertrand et al., 2002). Functionally redundant and compensatory roles by members 
of the NeuroD family of proteins is possible due to firstly, the high sequence similarity 
within their bHLH domains that are required for DNA binding and dimerisation and 
secondly, the highly overlapping expression profiles of NeuroD family members 
across several brain regions. To study functional redundancy and compensation 
between more than one NeuroD factor, simultaneous inactivation of more than one 
member has been conducted. The phenotypes of double mutants have been 
compared to those of individual single gene inactivation.  
Since Neurod6 single mutants generated by Schwab et al., (1998) did not exhibit any 
obvious abnormalities (Schwab et al., 1998), they generated Neurod1/6 double 
mutants (Schwab et al., 2000) since these two factors exhibited overlapping 
expression patterns within the neocortex, hippocampus and cerebellum (Schwab et 
al., 1998; Schwab et al., 2000). Although Neurod1/6 double mutant mice died shortly 
after birth due to Neurod1-deficiency causing pancreatic failure, Neurod1/6 double 
mutants revealed redundant functions of these two factors specifically in the terminal 
neuronal differentiation of hippocampal granule cells (Schwab et al., 2000).  
Neurod2/6 double-deficient mice were generated by Bormuth et al., (2013) to study 
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their redundant roles in cortical commissure formation. Neurod2/6 double mutant 
mice exhibited several defects in late neuronal functions including disorganization of 
dendritic morphology, reduction of glutamatergic synapses and impairment of 
commissural tract formation (Bormuth et al., 2013). Together, these findings 
demonstrated that NEUROD2 and NEUROD6 are both required for the fasciculation 
and directional growth of callosal axons in the mouse neocortex (Bormuth et al., 
2013).  
This far, I have reported the expression and role of Neurod6 in the survival of a 
subset of mDA neurons. However, many brain regions usually express more than 
one bHLH member of the NeuroD family of transcription factors. Furthermore in the 
absence of Neurod6, only ~30% of the Neurod6-subset of mDA neurons as seen by 
YFP expression are lost in Neurod6Cre/Cre;R26RYFP/YFP mutants. Together this could 
indicate towards the possibility of another bHLH member of the NeuroD family being 
expressed within this mDA subset with potential compensatory roles for the survival 
functions of Neurod6 in the remaining surviving YFP neurons of Neurod6 mutants.  
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5.2 Results 
 
5.2.1 Neurod1 is broadly expressed by mDA neurons 
 
Since Neurod family members share redundant roles in other parts of the nervous 
system, we next addressed the possibility that another Neurod gene promotes the 
survival of a subset of Neurod6+ neurons in Neurod6 mutants. We first examined the 
expression profiles of NEUROD1 and NEUROD2 in mDA neurons. Neurod1 
transcripts were detected by in situ hybridisation strongly in immature and weakly in 
mature mDA neurons at E13.5 and E14.5 (Figure 5-1A,B). NEUROD1 expression 
analysed by immunohistochemistry of Neurod6Cre/+;Rosa26RYFP/YFP
 
embryos was 
maintained in all mature TH+ mDA neurons including YFP+ (Neurod6+) mDA 
neurons at E18.5 (Figure 5-1C). In addition, in situ hybridization of Neurod1 followed 
by immunohistochemistry of TH showed that this expression was maintained into the 
adult stage (Figure 5-1D). In contrast, NEUROD2 analysed by 
immunohistochemistry, was not expressed in mDA neurons at E18.5 (Figure 5-
2A,B).  
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Figure 5-1 Neurod1 is expressed in mDA neurons 
A,B, In situ hybridization show that Neurod1 transcripts are expressed strongly and 
weakly respectively in immature and mature (arrows) in mDA neurons located 
ventral to the floor plate of the midbrain at E13.5 (A) and E14.5 (B). C,D, This 
expression, detected by triple immunolabeling with NEUROD1, TH and YFP 
antibodies, is maintained in mature YFP+ and TH+ mDA neurons at E18.5 and in 
adult Neurod6 control mice by in situ hybridization of Neurod1 followed by 
immunohistochemistry of TH. Scale bar 100μm. 
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Figure 5-2 Neurod2 is not expressed in mDA neurons 
A, NEUROD2 was not detected in mDA neurons and, B, in only sporadic TH- cells 
at E18.5 by immunohistochemistry in sections of central (A) and rostral (B) mDA 
regions. Scale bar 100μm. 
 
 
5.2.2 Severe loss of Neurod6+ VTA neurons in Neurod1 and Neurod6 double 
mutants  
To determine whether Neurod1 is required for the survival of Neurod6+ mDA 
neurons, we used mice carrying a null allele of Neurod1 whereby LacZ replaces the 
Neurod1 coding sequence (Naya et al., 1997; Miyata et al., 1999) to generate 
Neurod1 and Neurod6 (Neurod1;Neurod6) double mutant mice 
(Neurod1LacZ/LacZ;Neurod6Cre/Cre;R26R). The double homozygous mutants died 
shortly after birth at P0, as the Neurod1LacZ/LacZ single mutants that die from neonatal 
diabetes (Miyata et al., 1999). We therefore examined Neurod6+ VTA neurons at 
E18.5 and observed a severe loss of YFP+/TH+ mDA neurons in the VTA of 
Neurod1;Neurod6 double homozygous mutants (Figure 5-3F,G) compared to both 
control (Figure 5-3A,G) and Neurod6Cre/Cre
 
single mutant embryos (Figure 5-3B,G), 
which do not show a cell loss at this stage. Moreover, mice homozygous mutant for 
Neurod1 and heterozygous for Neurod6 (Neurod1LacZ/LacZ;Neurod6Cre/+) as well as 
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mice homozygous mutant for Neurod6 and heterozygous for Neurod1 
(Neurod1LacZ/+;Neurod6Cre/Cre) and double heterozygous (Neurod1LacZ/+;Neurod6Cre/+) 
mice also present significant losses of YFP+/TH+ mDA neurons compared to 
Neurod6Cre/Cre
 
single mutants at E18.5 (Figure 5-3D-F respectively and Figure 5-3G). 
These results suggest that both Neurod1 and Neurod6 contribute to the survival of 
VTA Neurod6+ neurons before birth, since loss of one copy of each gene reduces 
neuronal viability. They also suggest that Neurod1 has a more important role than 
Neurod6 in Neurod6+ neuron survival, since loss of one copy of Neurod1 and one 
copy of Neurod6 results in the loss of some neurons while loss of two copies of 
Neurod6 has no effect at E18.5. However, the early postnatal death of double mutant 
mice precluded the analysis of mDA neurons and axonal projections at later stages. 
Earlier analysis of double mutant embryos was also not feasible since YFP, which 
serves to mark Neurod6+ mDA neurons, only becomes detectable at E18.5 (data not 
shown).  
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Figure 5-3 Neurod1 is also required for the survival of Neurod6+ mDA neurons. 
A-F, YFP+,TH+ mDA neurons are lost at E18.5 in Neurod1;Neurod6 double 
mutants carrying different copy numbers of Neurod1 and Neurod6 mutant alleles. 
Immunohistochemistry of YFP and TH shows that reduced numbers of YFP+/TH+ 
mDA neurons are observed in coronal sections of the central midbrain in double 
mutant embryos carrying 2 (C), 3 (D,E) or 4 Neurod1;Neurod6 mutant alleles (F). In 
contrast, Neurod6 single homozygous mutants present no change in YFP+/TH+ 
expression in mDA neurons at E18.5 (B). G, Bar graph showing percentage 
changes of the number of YFP+/TH+ mDA neurons in the central mDA region of 
Neurod1;Neurod6 double and Neurod6 single mutant embryos normalised to 
Neurod6Cre/+ control embryos. Error bars denote SEM. N=3 per genotype. 
Chapter 5. Results 
 
 116 
*p<0.05; **p<0.01; ***p<0.0001 (one-way ANOVA, with Tukey’s post-test). Scale 
bar 100μm.  
 
5.3 Discussion 
 
Genetic studies have revealed that Neurod6 alone is required for the survival of 
LSi-projecting Neurod6+ mDA neurons postnatally (see previous chapter), while 
the survival of Neurod6+ mDA neurons are dependent on both Neurod1 and 
Neurod6 embryonically as demonstrated in this chapter. Together, these results 
have revealed essential roles for NEUROD-family proteins in regulating the survival 
of this mDA neuronal subset. 
Since NEUROD1 is also expressed in both immature and mature mDA neurons 
during development and since Neurod6+ mDA neurons are partially lost in Neurod6 
single mutants, we also analysed the phenotypes of Neurod1;Neurod6 double 
mutant mice. Severe loss of Neurod6+ mDA neurons occurred in double 
homozygous mice at E18.5, i.e. before the cells are lost in Neurod6 single mutants. 
Neurod6+ mDA neurons were also lost in double heterozygous mice and in mice 
homozygous for the Neurod1 mutation and heterozygous for the Neurod6 mutation. 
Because of the unavailability of NEUROD6-specific antibodies, we cannot determine 
the status of Neurod6+ mDA neurons in Neurod1 single mutants. Together, our 
genetic analysis demonstrates that both Neurod6 and Neurod1 contribute to the 
survival of Neurod6+ mDA neurons.  It also suggests that Neurod1 has a more 
important role than Neurod6 for Neurod6+ mDA neuronal survival at E18.5 since loss 
of the two copies of Neurod6 has no effect while loss of one copy of Neurod1 and 
one copy of Neurod6 reduces survival of these neurons.   
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Further studies will be required to identify the mechanisms through which 
NEUROD family proteins regulate the survival of embryonic mDA neurons during 
development and to determine whether these proteins continue to have a survival 
role in these neurons during adult life.  
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Chapter 6. Discussion 
DA neuron diversity is a challenging field of immense importance for understanding 
DA related neuropsychiatric disorders. The work presented in this thesis describes a 
subset of DA neurons, defined by a new marker Neurod6. I have characterised the 
expression of this marker, correlated it with other markers, and demonstrated that 
these neurons project to the septum. I then determined that in mice lacking NeuroD6, 
this subset is partially lost. This mild phenotype is exacerbated in Neurod1;Neurod6 
double mutants.  
 
This study investigates the role of bHLH protein NEUROD6 in the development of a 
subset of DA neurons in the VTA of the ventral midbrain. Using in situ hybridisation, 
RNAscope-TH double labelling and Neurod6Cre/+;R26RYFP/YFP mice, I have shown 
that NEUROD6 is indeed co-expressed in a subset of DA neurons in the VTA, which 
co-express OTX2, CALBINDIN and ALDH1A1. I have then used 
Neurod6Cre/Cre;R26RYFP/YFP mutant mice to show that loss of NEUROD6 reduces 30% 
of Neurod6+ mDA neurons in VTA, due to an increase in cell death. Using TH 
staining and FG retrograde labelling, I have postulated that the Neurod6+ mDA 
neurons projected their axons to specific regions in the LS. Finally, I have 
demonstrated that removing NeuroD1, further eliminated all the NeuroD6+ neurons 
in the VTA, suggesting functional redundancy of NeuroD1 in promoting the survival 
of NeuroD6+ mDA neurons. 
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6.1 Neurod6 defines a new VTA-specific mDA subset 
In the analysis of YFP-labelled Neurod6+ mDA neurons in Neurod6 controls, I have 
defined the localisation of these neurons to the ventral midbrain in specific VTA 
nuclei mostly in the dorsal and ventral components of the PN and IF as well as some 
in the lateral PBP (Chapter 3). Furthermore, I have molecularly identified these 
Neurod6+ mDA neurons with other known molecular markers of the VTA and have 
demonstrated that majority of Neurod6+ neurons define a new subset of Otx2+, 
Calbindin1+, Aldh1a1+, Nolz1+ and Grp+ VTA mDA neurons.  
Single-cell gene profiling of global mDA neurons using microfluidic dynamic array 
technology followed by RT-qPCR of 96 genes revealed 6 unique mDA subtypes 
(Poulin et al., 2014). Principle component analysis grouped these 6 mDA subtype 
expressing combination of key genes into DA1A, DA1B, DA2A, DA2B, DA2C, and DA2D 
subtypes (Poulin et al., 2014). According to these gene expression profiles, Neurod6 
likely belongs to the DA2B subtype of mDA cells based on their expression of Otx2 
and Aldh1a1. In addition to these markers, I have shown that Neurod6+ mDA 
neurons also co-express Grp and Nolz1 suggesting that the DA2B subtype is a VTA-
specific mDA subtype with a more complete molecular signature: Otx2+, Aldh1a1+, 
Nolz1+, Grp+ and Neurod6+ VTA neurons. Other molecular markers detected in this 
DA2B subtype also includes Lpl (Poulin et al., 2014), supporting the possibility that 
Lpl is also expressed in Neurod6+ mDA neurons.  Co-localisation of YFP+ cells in 
Neurod6 controls with Adcyap1 would further support this molecular identity of the 
DA2B subtype and support Neurod6 as a new molecular marker for this mDA 
subtype.  
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Aldh1a1+ VTA mDA neurons synthesise GABA, independent of GAD, for co-release 
with DA (Kim et al., 2015). Since Neurod6+ VTA neurons are part of the Aldh1a1+ 
mDA subset and co-localise with ALDH1A1, it remains to be determined whether 
Neurod6+ VTA neurons are able to synthesise and co-release both DA and GABA 
in the LS.  
More importantly, the DA2B mDA subtype described by Poulin et al., (2014), which 
likely includes Neurod6, is shown to be resistant to MPTP-treatment further 
supporting neuroprotective functions for VTA DA2B molecular signature markers 
(Poulin et al., 2014).  
 
Given that the Neurod6 VTA subset can fundamentally be divided into two subsets; 
one requiring Neurod6, the other requiring both Neurod6 and Neurod1 for survival, it 
is likely that this Neurod6-marked mDA subset represents two unique subsets with 
differential expression of molecular proteins in addition to distinct axon target sites 
(LSi and LSd) and their differential requirements for Neurod6 and Neurod1 bHLH 
proteins. Single-cell analysis of this Neurod6 subset may elucidate differentially 
expressed genes between LSi- and LSd- projecting Neurod6+ VTA neurons. 
Chapter 6. Discussion 
 
 121 
 
Figure 6-1 Summary of Neurod6+ mDA neurons projecting to LS and differential 
requirements for their survival.  
Neurod6+ mDA neurons of the VTA project to the dorsal and intermediate 
components of the LS (A). Neurod6 is not required for the survival of LSd-
projecting mDA neurons which survive in Neurod6 mutants probably due to 
compensation by Neurod1 (B). Neurod6 is only required for the survival of LSi-
projecting mDA neurons which are lost in Neurod6 mutants (C). In the absence of 
both Neurod6 and Neurod1, both subsets are lost (not shown). 
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6.2 The LS in the forebrain is a projection target of Neurod6+ 
VTA mDA neurons 
Several studies have described DA innervations in the LS (Lindvall, 1974; Onteniente 
et al., 1984; Lindvall and Stenevi, 1978) originate from the VTA (Assaf and Miller, 
1977; Lindvall et al., 1977; Carter and Fibiger, 1977; Fallon and Moore, 1978). 
However, the work reported in this thesis is the first to molecularly identify this VTA 
subset(s) projecting to discrete regions within the LS – both the LSi and LSd – with 
their specific expression of the Neurod6 bHLH transcription factor protein. 
Furthermore, the requirements for NeuroD proteins is different between LSi and LSd-
projecting VTA neurons. In summary, my results show that NeuroD6-expressing 
mDA neurons are localised within the medial VTA in specific nuclei and project to 
both the LSd and LSi. In the absence of NeuroD6, ~30% cells die within the dorso-
medial PN component of the VTA, which correlates with mDA axon loss within the 
LSi. These neurons require NeuroD6 for their survival. Furthermore, in the absence 
of Neurod6, YFP cells in ventro-lateral PN component of the VTA survive & these 
project to the LSd. These neurons do not require Neurod6 for survival probably due 
to compensation by Neurod1. In the absence of both Neurod1 and Neurod6 in double 
mutants, most of this Neurod6-marked subset is lost. Over several years of DA 
research, it seems the LS is an mDA projection target has not been extensively 
studied at the functional level. Here is the first report of a target-specific (LS), 
molecular marker- defined (Neurod6) functional mDA subset. The next implication of 
this subset is elucidating its behavioural function and relevance to 
neurodevelopmental and neuropsychiatric disorders of the limbic system, which is 
beyond the scope of this thesis.  
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It remains to be determined whether Neurod6+ mDA neurons projecting to the LS, 
also send axon collaterals to other regions within the forebrain. VTA neurons of the 
PN can project their axons exclusively to the LS (Aransay et al., 2015) or send axonal 
branching to NAc as detected by single-cell axon tracing methods (Aransay et al., 
2015). There were no observed changes in TH+ antibody labelling of mDA axons in 
any other forebrain targets other than the LS in Neurod6 mutants. TH+ immuno-
labelling of axons did not show any obvious change in projections to the NAc in 
Neurod6 mutants compared to controls suggesting Neurod6+ VTA neurons from the 
PN project exclusively to the LS. However, if these axons do send collaterals to NAc, 
these may not be obvious. To address this, Cre- dependent anterograde tracing of 
Neurod6+ mDA axons could identify if there is also axonal branching to NAc regions.  
The findings that Otx2 is required for the upregulation of axon guidance molecules 
in VTA mDA neurons as well as loss of mDA axons in several VTA-specific forebrain 
target areas including both the LSd and LSi of Otx2 cKO mice (Chung et al., 2010), 
suggests the requirement of Otx2 function in LS-projecting Neurod6+ Otx2+ VTA 
neurons. The precise mechanisms by which Otx2 establishes correct projection 
targeting patterns of VTA neurons and whether this is independent of other 
transcription factors in VTA subsets is not understood. In addition to Neurod6’s role 
in mDA neuronal survival, whether it has any additional roles in regulation of axon 
guidance of VTA neurons to the LS is unknown. Furthermore, Neurod2/6 regulate 
commissural formation in the cortex by regulating axon guidance molecules 
(Bormuth et al., 2013). Future experiments could investigate additional roles for 
Neurod1/6 in mDA axon guidance to the LS aside from their role in their survival.   
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6.3 Candidate mechanisms for Neurod6-mediated neuronal 
survival of VTA neurons 
In the absence of Neurod6, approximately 30% of VTA neurons are lost in Neurod6 
mutants shortly after birth at P2 due to cell death as seen by TUNEL analysis 
(Chapter 4). Determining the mechanism of Neurod6-mediated neuronal survival of 
mDA neurons of the VTA will facilitate our understanding of multiple pro- neuronal 
survival/ anti-apoptotic pathways. This could shed light on how the presence of these 
factors may make VTA mDA neurons more resilient to degeneration, in contrast to 
the absence of these factors, in SNc neurons, which are more susceptible to cell 
death. 
 
6.3.1 PI3K/Akt signalling  
 
Calbindin-D28K is a neuroprotective factor for CB-positive VTA neurons (Sun et al., 
2011) compared to CB-negative SNc neurons that are more susceptible to 
degeneration in PD (German et al., 1992). The neuroprotective effects of CB on VTA 
mDA neurons is mediated by the activation of PI3-Kinase-AKT signalling pathway 
(Sun et al., 2011). PI3K/Akt signalling promotes survival by generation of 
phosphatidylinositol 3,4,5-triphosphate by PI3K, which activates Akt by 
phosphorylation of Ser-473 (Alessi et al., 1996). Activated Akt is able to influence the 
activity of downstream factors including caspase 9 and CREB thereby promoting 
neuronal survival (Datta et al., 1999). It is possible that Calbindin-D28K and Neurod6 
act on the same pathway to inhibit apoptosis in VTA neurons and provide 
neuroprotective roles.  
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The Aldh1a1 enzyme synthesises RA in neurons. ALDH1A1 expression in mDA 
progenitor cells and mature VTA neurons in the adult begs the question of the role 
of RA in early and late mDA development and in Aldh1a1+/Neurod6+ VTA neurons. 
In a human neuroblastoma cell differentiation model, RA induces neural 
differentiation by modulation of bHLH factors (Lopez-Carballo et al., 2002). 
Specifically, RA down-regulates ID1, ID2 and ID3 genes that usually inhibit neural 
differentiation and down-regulates the neuroblastoma marker Mash1 (Lopez-
Carballo et al., 2002). In contrast, RA induces an increase in mRNA levels of neural 
differentiation-promoting bHLH factors Neurod6 and Neurod1 (Lopez-Carballo et al., 
2002) by rapid activation of the PI3K/Akt signalling pathway (Lopez-Carballo et al., 
2002). Firstly, this may implicate early roles for Aldh1a1 in mDA progenitors for RA- 
activation of neural differentiation by induction of pro-differentiation factors such as 
Neurod1 (onset of expression strongly in immature and weakly in mature TH+ 
neurons at E13.5) and Neurod6 (onset of expression in already mature TH+ neurons 
at E15.5). Secondly, a late role of Aldh1a1 may be in promoting neuronal survival of 
Neurod6+/Aldh1a1+ VTA neurons via RA-induced activation of the PI3K/Akt 
signalling pathway. Neurod6 may be acting on this same pathway to mediate 
neuronal survival or independently of Akt via regulation of mitochondrial proteins.  
 
6.3.2 Regulation of mitochondrial pathways 
 
The mechanisms of Neurod6-mediated neuronal survival have been extensively 
studied in an established Neurod6-overexpressing rat PC12 pheochromocytoma cell 
line model system (Uittenbogaard and Chiaramello, 2005). Neurod6-mediated 
survival of PC12 cells is independent of PI3K/Akt signalling since Neurod6-PC12 
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cells fail to express phosphorylated forms of Akt in a serum deprivation experimental 
cell death paradigm (Uittenbogaard and Chiaramello, 2005). Instead, Neurod6 
activates an anti-apoptotic program at two distinct regulatory levels of the 
mitochondrial pathway to promote neuronal survival by inducing the expression of 
the Bcl-w and XIAP anti-apoptotic pro-survival proteins (Uittenbogaard and 
Chiaramello, 2005). Neurod6 induces mitochondrial biogenesis and the expression 
of bioenergetics-related genes upon Neurod6 onset of expression during early 
stages of neuronal differentiation (Baxter et al., 2012). Furthermore, Neurod6 
increases the mitochondrial membrane potential and ATP levels and confers 
tolerance to oxidative stress (Baxter et al., 2012). A working model of Neurod6-
mediated neuronal survival via regulation of mitochondrial functions was published 
by Uittenbogaard et al., (2010) and is referenced here (Figure 6-2; Uittenbogaard et 
al., 2010).  
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Figure 6-2 Working model of Neurod6-mediated neuronal survival and resistance 
to oxidative stress in PC12 cells (cited from Uittenbogaard et al., 2010) 
 
 
 
The timing of onset of Neurod6 expression at E15.5 in VTA neurons coincides with 
timing of axonal targeting to forebrain structures. This is a less understood energy 
demanding process in mDA development possibly requiring mitochondrial bioenergy 
reserves and increased ATP production. There is evidence to support a high demand 
for ATP during the development of mDA neurons (Pacelli et al., 2015), In support of 
this, prior to cell death of VTA neurons at P2, densitometry of TOM-20 fluorescence 
reveals a significant reduction in the mitochondrial mass of YFP labelled mDA cells 
in Neurod6 mutants that no longer express Neurod6 at E18.5 compared to YFP+ 
cells in controls still expressing Neurod6 (Chapter 4). Reduced mitochondrial mass 
at this stage could just be a consequence of activation of cell death programs or as 
a direct result of dysregulation of Neurod6-controlled mitochondrial integrity. If this 
was the case, Neurod6 would not be the first to promote an anti-oxidative stress 
modulation of mitochondrial function in post-mitotic differentiated mDA neurons. 
Lmx1a/b transcription factors also modulate mitochondrial function to promote 
survival of adult mDA neurons (Doucet-Beaupre et al., 2016). Inactivation of Lmx1a/b 
results in reduced respiratory chain activity, increased oxidative stress, mitochondrial 
DNA damage and dysfunction resulting in degenerative loss of mature mDA neurons 
(Doucet-Beaupre et al., 2016).  
NeuroD6 may be neuroprotective for VTA neurons and could regulate their survival 
by making them less resistant to mitochondrial oxidative stress via the upregulation 
of pro-survival and anti-apoptotic factors and mediating an anti-oxidant response. 
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Overexpression of Neurod6 using a Cre-inducible system in differentiated mDA cell 
cultures from mouse embryonic stem (ES) cells could provide mechanistic insights 
into Neurod6-mediated mDA neuronal survival in a dopamine context.  
 
6.4 Functional redundancy of Neurod1 in promoting survival of 
Neurod6+ mDA subset 
Neurod6 alone is required for the survival of LSi-projecting mDA neurons, however 
some Neurod6+ neurons still develop normally in Neurod6 mutant mice and send 
axons to the LSd (see Chapter 4). Given this partial loss of Neurod6+ mDA neurons, 
I also generated and analysed Neurod6 and Neurod1 double mutant embryos and 
found that Neurod1 also regulates the survival of the Neurod6+ mDA neurons (see 
Chapter 5).  
Functional redundancy of bHLH transcription factors of the the NeuroD family have 
been documented in other regions of the brain in specific neuronal populations. For 
example, Previously generated Neurod1/6 double mutant mice provide evidence that 
Neurod1 and Neurod6 are functionally redundant in the granule cells of the 
hippocampus (Schwab et al., 2000). In the Neurod6/1 double mutants generated in 
this work, Neurod1-deficiency leads to the elimination of almost all surviving 
Neurod6+ mDA cells suggesting that Neurod1 is functionally redundant in promoting 
the survival of a proportion of Neurod6+ mDA neurons, most likely those that project 
to the LSd.  
6.4.1 Neurod1/6 expression and role in survival described for the first time 
in mDA neurons 
This thesis describes for the first time the spatiotemporal expression profiles of 
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Neurod1, Neurod2 and Neurod6 in the ventral midbrain and demonstrates the role 
of Neurod6 and Neurod1 in mDA neuronal survival. Previous studies have only 
documented their expression profiles in cortical, hippocampal, cerebellar regions 
(Schwab et al., 1998; Gao et al., 2009; Bormuth et al., 2013) of the CNS and others 
in the PNS.  
Neurod2 and Neurod6 share redundant roles in the cortex where they are co-
expressed in all post-mitotic projection neurons (Bormuth et al., 2013). Majority of 
callosal projection neurons survive until birth in Neurod2/6 double mutants however 
their axons stall within the SVZ of the cingulate cortex and fail to turn ventrally 
towards the midline (Bormuth et al., 2013). Neurod2/6 double mutants exhibit 
absence of cortical fiber tracts, defasiculation of callosal axons and permanent 
agenesis of the corpus callosum (Bormuth et al., 2013) due to changes in differential 
expression of axon guidance molecules Ctn2 (downregulated in mutants) and Robo1 
(upregulated in mutants) of collasal projections (Bormuth et al., 2013).  
Given these redundant functions of Neurod2/6 in cortical development, I also 
analysed the expression of Neurod2 in the VTA of Neurod6 control embryos. In 
contrast to NEUROD1 and Neurod6 (YFP), NEUROD2 was not expressed by mDA 
neurons at E18.5 and was sporadically expressed in TH-negative (possibly 
GABAergic) cells in rostral and central midbrain sections.  
Neurod1/6 double mutant mice reported previously by Schwab et al., (2000) 
displayed a severe lack of the dentate gyrus which prompted a detailed study of the 
hippocampus. Defects in the total number of cells within the hilar region and of 
migratory granule cell precursors was more severe in Neurod1/6 double mutants 
which exhibited 30% further reduction in hilar region cell numbers compared to 
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Neurod1 single mutants (Schwab et al., 2000). Furthermore, these neurons fail to 
mature and degenerate as a result of cell death since the number of observed 
TUNEL+ cells were 7.5-fold higher in the hilar region of Neurod1/6 double mutant 
hippocampal sections compared to wild-type (Schwab et al., 2000).  
Neurod6 single mutants have a 30% loss of cells in the central mDA region due to 
cell death as demonstrated by increased TUNEL+ staining at P2 in the absence of 
Neurod6. Neurod6+ VTA neurons co-express NEUROD1 in the midbrain of E18.5 
embryos. Neurod6/1 double mutants display a nearly complete loss of the Neurod6+ 
mDA subset. This is in support of partial functional redundancy like that observed in 
hippocampal granule cells only here Neurod1 may be able to partially compensate 
for Neurod6 in the remaining 70% of Neurod6+ mDA neurons that usually survive in 
Neurod6 mutants. 
 
6.4.2 Inactivation of Neurod1 in adult Neurod6+ mDA neurons to assess 
changes in DA axons to LSd 
Since Neurod1;Neurod6 double mutants die shortly after birth, it would be useful to 
use an inducible gene ablation approach to study the mechanism of functional 
redundancy of Neurod1 in the Neurod6+ mDA subset. For this purpose, Neurod1flox 
mice (Goebbels et al., 2005) are now being crossed with 
Neurod6Cre/+;R262RYFP/YFP mice for tamoxifen-induced inactivation of Neurod1 
in adult Neurod6+ mDA neurons to further dissect the mechanisms of Neurod1/6-
mediated mDA neuronal survival and maintenance. Since in E18.5 embryos, mDA 
projections to the LS have not yet arrived at this stage, this precluded the analysis of 
LS-projecting axons in Neurod6/1 double mutants. Using a conditional Neurod1flox 
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line (Goebbels et al., 2005) instead to generate Neurod6;Neurod1 double mutants 
and inactivating Neurod1 later in Neurod6+ mDA neurons, would enable analysis of 
the role of Neurod1 in LSd-projecting Neurod6+ VTA neurons.  
 
6.4.3 Investigating Neurod6/1 interactions in mDA domain 
Expression analysis by in situ hybridisation and antibody labelling shows a much 
broader expression pattern for Neurod1 which is expressed in all mDA neurons of 
both the VTA and SNc (Chapter 5). It is unknown whether Neurod1 has functions 
independent of Neurod6 in mDA neurons outside of the Neurod6 mDA subset in 
TH+/ Neurod6- neurons. Since Neurod1 has broader expression pattern and is 
expressed earlier in high levels in immature mDA cells and lower levels in mature 
mDA cells at E13.5, Neurod1 may be important for the induction of mDA neuron 
terminal differentiation from immature to mature states.  
In support of this, analysis of human umbilical cord of full-term births by 
immunocytochemistry and western blots revealed an upregulation of TH (mature 
marker), Nurr1 (both immature and mature marker) and Neurod1 upon mDA neuron 
induction (Paldino et al., 2014). Treatment with forskolin, a natural reagent that 
activates the adenylyl cyclase enzyme and increases the intracellular levels of 
second messenger cAMP, resulted in the upregulation of neurotrophin Trk receptors 
and an increased release of BDNF (Paldino et al., 2014). This is the only study to 
date to mention Neurod1 involvement in mDA neurons.  
 
In addition, Neurod1 is expressed earlier at E13.5 than Neurod6 which is detected in 
mDA neurons of VTA at E15.5, this could suggest that Neurod1 is upstream of 
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Neurod6. To test if Neurod1 controls Neurod6 expression in mDA neurons or is 
required for their survival independent of Neurod6, analysis of Neurod6 mRNA 
transcript levels in the mDA domain of Neurod1 single mutants by in situ hybridisation 
would reveal either a downregulation of Neurod6 or no change in Neurod6 
expression, which could suggest that the two act independently of each other or 
whether they do indeed interact. Comparing numbers of Neurod6+ mDA cells in 
Neurod1 single mutants would give further insights into Neurod6-independent 
Neurod1-mediated survival of Neurod6+ mDA neurons. 
 
6.4.4 Comparisons to other transcription factor pairs in mDA development 
In contrast to many of the other transcription factor pairs that are required for mDA 
development such as Foxa1/2, Lmx1a/b and En1/2, results suggest Neurod1/6 only 
act together in post-mitotic mature mDA neurons. Foxa1/2 for example, are required 
at multiple stages of mDA development for the specification of mDA progenitors, the 
early differentiation into immature and late differentiation into mature mDA neurons 
(Ferri et al., 2007). This requirement for Foxa genes is dosage-dependent since 
higher concentrations (more allelic copies) of Foxa1/2 are required at later stages of 
mDA development and therefore the timing and duration of mDA differentiation is 
regulated by Foxa1/2 (Ferri et al., 2007).  
In contrast, the effects of Neurod6 and Neurod1 seem late acting on differentiated 
mDA neurons. Considering Neurod6;Neurod1 mutant analysis of TH+/YFP+ cell 
numbers at E18.5 (Chapter 5) shows proportional changes in the percentage of 
TH+/YFP+ cells with varying allelic-inactivation combinations, raises speculation that 
Neurod6 and Neurod1 may regulate mDA neuron survival in a gene dosage-
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dependent manner. Several other transcription factor pairs regulate mDA survival 
including Foxa1/2, Lmx1a/b, En1/2 and now Neurod1/6. 
 
6.5 Towards understanding behaviour: Functional implications 
for Neurod6+ VTA subset 
Neurod6+ mDA neurons identify a novel subset in the VTA characterised by the 
expression of unique molecular markers and the innervation of these neurons on to 
the LS in the forebrain. The role of Neurod6 itself in these mDA neurons is that of 
survival. However, the functional relevance of this Neurod6-defined VTA subset of 
DA neurons remains to be uncovered. Assessing the function of this population 
would enhance the significance of this work.  
Although the selective expression of Neurod6-Cre reported here will likely become a 
highly effective tool to characterise subsets of DA neurons in the VTA and their 
physiological function, this mouse line was also a major limitation in elucidating the 
function of this Neurod6+ mDA subset of neurons in a behavioural context. This is 
because in Neurod6 mutants, the absence of Neurod6 is not unique to mDA neurons 
but Neurod6 expression is absent from all other brain regions where Neurod6 would 
usually be expressed including the cortex, hippocampus, hypothalamus, and 
cerebellum (Goebbels et al., 2006). This thereby precluded the behavioural analysis 
of Neurod6 mutants to determine the functional relevance of Neurod6+ mDA neurons 
that project to the LS.  
6.5.1 Viral and genetic approaches for future behavioural studies 
To study the function of mDA-specific Neurod6+ neurons, injections of Cre-
dependent Designer Receptor Exclusively Activated by Designer Drugs (DREADDs) 
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in the VTA region for either activation of inactivation of these neurons in 
Neurod6Cre/+;R26RYFP/YFP mice or the use of Cre-dependent channel rhodopsin and 
optogenetics of these neurons could be employed in future work. Alternatively, dual-
recombinase genetic intersectional approaches also allow for high selectivity for 
labelling DA subsets (reviewed in Dymecki et al., 2010). In a dual-recombinase 
approach, two site-specific recombinases rather than one are required to activate a 
reporter transgene (Dymecki et al., 2010) and only the cells contained in the overlap 
between expression patterns driven by the Cre and the Flpe transgenes are selected 
for fate mapping (Dymecki et al., 2010). This approach would enable the detection 
of the ‘activated’ dual-recombined constitutively expressed GFP reporter transgene 
as the double-positive (for example, TH+/NeuroD6+) cells.  
 
6.5.2 Functional relevance for LS-projecting Neurod6+ mDA subset in 
stressful, social and addictive behaviours 
Limited studies have reported observations of elevated extracellular DA levels and 
increased DA releasability in the LS as a result of the actions of several drugs. The 
co-release of GABA and DA from non-canonical synthesis of GABA (Kim et al., 2015) 
in Aldh1a1+/Neurod6+ VTA neurons should also be explored in the context of alcohol 
consumption and dependency. Future work should explore behaviours relevant to: 
(i) Addiction particularly those linked to amphetamine (Renard et al., 2014), cocaine 
(Reddy et al., 2016), morphine self-administration (Le Merrer et al., 2007), and 
alcohol consumption (Kim et al., 2015), (ii) Sensory information processing of stress 
(Adams and Moghaddam, 2000) or of (iii) septo-hippocampal modulation and 
learning (Robinson et al., 1979; Yamamuro et al., 1995).  
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6.6 Final Remarks  
The understanding of heterogeneity of mDA neurons particularly of VTA-specific 
molecular subsets links to wider implications of the molecular identities of DA neurons 
to reward-based behaviours and several clinical conditions in addiction, social stress and 
depressive states. Dissecting molecular subsets of VTA neurons also contributes 
towards building our understanding of neuronal survival and neuroprotective 
mechanisms in mDA neurons. It is well established that VTA neurons are more protected 
in neurodegeneration. In PD, SNc neurons are highly susceptible to neuronal death 
compared to VTA neurons that are clearly more resilient. Unravelling the factors that 
constitute VTA mDA neurons more resilient to cell death by regulation of neuronal 
survival via mitochondrial pathways, activation of anti-apoptotic programs and protection 
against oxidative stress during their development, will aid our understanding of 
therapeutic targets and requirements for mDA neuron survival and regeneration in the 
treatment of DA-related neurodegenerative and neuropsychiatric disorders. Furthermore, 
dissecting unique and overlapping DA circuit pathways by genetic tools that label 
individual DA populations at the molecular level will aid discrimination of limbic system 
psychiatric behavioural conditions that present with very similar symptoms. Together, 
these could aid not just therapy towards reward-based DA functions of the limbic system 
but also perhaps cell-based therapy for mDA protection in neurodegeneration.  For these 
reasons, mDA heterogeneity is an important and expanding field and dissecting 
complexity of dynamic subsets and their projection patterns work towards a bigger 
picture of how DA neurons in the brain regulate human physiological, behavioural and 
psychological functions. 
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Chapter 7. Appendix 
7.1 The levels, expression profiles and functions of DA 
receptors in the brain (summarised from Beaulieu and Gainetdinov, 2011) 
 
DA receptor 
subtype: 
Level of 
expression: 
Brain areas expressed in: Functions: 
D1 High nigrostriatal, mesolimbic, and 
mesocortical areas, such as the 
caudate-putamen (striatum), NAc, 
SN, olfactory bulb, amygdala, and 
frontal cortex 
locomotor activity, 
reward and 
reinforcement, 
learning and memory 
Low hippocampus, cerebellum, thalamic 
areas, and hypothalamic areas 
D5 Low pyramidal neurons of PFC, the 
premotor cortex, cingulated cortex, 
entorhinal cortex, SN, 
hypothalamus, the hippocampus, 
and dentate gyrus 
cognitive functions  
Very low Medium spiny neurons (GABAergic) 
of the caudate nucleus and NAc 
D2 High striatum, NAc, the OT, SN, VTA, 
hypothalamus, cortical areas, 
septum, amygdala, and 
hippocampus 
locomotor activity, 
reward and 
reinforcement, 
learning and memory 
D3 High limbic areas, such as in the shell of 
the NAc, the OT, and the islands of 
Calleja 
locomotor activity, 
reward and 
reinforcement,  
cognitive functions  Low striatum, the SNpc, VTA,  
hippocampus, the septal area, and 
in various cortical areas 
D4 Lowest frontal cortex, amygdala, 
hippocampus, hypothalamus, 
globus pallidus, SNr and thalamus 
cognitive functions  
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7.2 Human proteins with basic helix-loop-helix DNA binding 
domain 
 
AHR  
AHRR  
ARNT  
ARNT2  
ARNTL  
ARNTL2  
ASCL1  
ASCL2  
ASCL3  
ASCL4  
ATOH1  
ATOH7  
ATOH8  
BHLHB2  
BHLHB3  
BHLHB4  
BHLHB5  
BHLHB8  
CLOCK 
EPAS1 
FERD3L  
FIGLA  
HAND1  
HAND2  
HES1  
HES2  
HES3  
HES4  
HES5  
HES6  
HES7  
HEY1  
HEY2  
HIF1A  
ID1  
ID2  
ID3  
ID4  
KIAA2018  
LYL1  
MASH1  
MATH2  
MAX 
MESP1 
MESP2  
MIST1  
MITF  
MLX  
MLXIP  
MLXIPL  
MNT  
MSC 
MSGN1  
MXD1  
MXD3  
MXD4  
MXI1  
MYC  
MYCL1  
MYCL2  
MYCN  
MYF5  
MYF6 
MYOD1  
MYOG 
NCOA1  
NCOA3 
NEUROD1  
NEUROD2  
NEUROD4  
NEUROD6  
NEUROG1  
NEUROG2  
NEUROG3  
NHLH1  
NHLH2  
NPAS1  
NPAS2  
NPAS3  
OAF1  
OLIG1  
OLIG2  
OLIG3  
PTF1A  
SCL  
SCXB 
SIM1  
SIM2  
SOHLH1  
SOHLH2  
SREBF1  
SREBF2  
TAL1  
TAL2  
TCF12  
TCF15  
TCF21  
TCF3  
TCF4  
TCFL5  
TFAP4  
TFE3  
TFEB  
TFEC  
TWIST1  
TWIST2  
USF1  
USF2 
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